

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification 7 : C12N 15/11, 15/63, 15/82, A01N 63/00, A01H 5/00</p>	<p>A1</p>	<p>(11) International Publication Number: WO 00/68374 (43) International Publication Date: 16 November 2000 (16.11.00)</p>
<p>(21) International Application Number: PCT/EP00/04117 (22) International Filing Date: 8 May 2000 (08.05.00) (30) Priority Data: 09/309,038 10 May 1999 (10.05.99) US (71) Applicant (for all designated States except AT US): NOVARTIS AG [CH/CH]; Schwarzwaldallee 215, CH-4058 Basel (CH). (71) Applicant (for AT only): NOVARTIS-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.H. [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT). (72) Inventors; and (75) Inventors/Applicants (for US only): HEIFETZ, Peter, Bernard [US/US]; 3916 Sturbridge Drive, Durham, NC 27713 (US). PATTON, David, Andrew [US/US]; 3506 Long Ridge Road, Durham, NC 27703 (US). LEVIN, Joshua, Zvi [US/US]; 1008 Urban Avenue, Durham, NC 27701 (US). QUE, Qiu-deng [CN/US]; 108 Forest Brook Drive, Apex, NC 27502 (US). DE HAAN, Petrus, Theodorus [NL/NL]; Kruideel 34, NL-1602 GI Enkhuizen (NL). GIELEN, Johannes, Jacobus, Ludgerus [NL/FR]; 6A, impasse Manet, F-31340 Aucanville (FR).</p>		<p>(74) Agent: BECKER, Konrad; Novartis AG, Patent and Trademark Dept. Agribusiness, Site Rosental, CH-4002 Basel (CH). (81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>
<p>(54) Title: REGULATION OF VIRAL GENE EXPRESSION (57) Abstract  The present invention relates to methods to alter the expression of a viral gene in a cell using sense and antisense RNA fragments of the gene. The sense and antisense RNA fragments are capable of pairing and forming a double-stranded RNA molecule, thereby altering the expression of the gene. The present invention also relates to cells, plants or animals, their progeny and seeds derived thereof, obtained using a method of the present invention. Preferably, such cells, plants or animals are resistant or tolerant to viruses.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

**REGULATION OF VIRAL GENE EXPRESSION**

The present invention relates to methods of altering the expression of viral genes in cells, plants or animals using sense and antisense RNA fragments of said genes, and to cells, plants or animals with altered viral gene expression obtained using the methods of the present invention. The invention particularly relates to such cells, plants or animals resistant or tolerant to viruses.

An area of deep interest is resistance or tolerance to viruses. Viruses affect most living organisms. In crops, large proportions of the harvest may be lost due to virus infections. Farm animals are also often infected by viruses and must sometimes be slaughtered to prevent spreading of the disease leading to dramatic economic consequences. Companion animals are also affected by viruses, and, finally, viruses infect humans causing a lot of suffering. Although treatments against viruses have been developed, they are very often either extremely expensive or of limited efficiency.

It is desirable to modify cells, plants or animals so that the expression of a particular viral gene is altered to create cells, plants or animals resistant or tolerant to said virus. Current methods to alter the expression of a gene usually rely upon techniques of sense or antisense suppression. Unfortunately, these methods are often variable and unpredictable in their ability to alter gene expression, and in many cases a complete disruption of the particular gene activity is not achieved.

There is therefore a long-felt but unfulfilled need for novel methods and compositions allowing one to effectively and predictably alter the expression of a viral gene to obtain cells, plants or animals with resistance or tolerance to viruses.

The present invention relates to methods of altering the expression of a viral gene in cells, plants or animals using sense and antisense RNA fragments of the gene. Importantly, such sense and antisense RNA fragments are capable of forming a double-stranded RNA molecule. Particularly, the present invention relates to methods and compositions of conferring upon a cell, plant or animal resistance or tolerance to viruses. Preferably the invention relates to methods of conferring upon a plant resistance or tolerance to viruses. The invention also preferably relates to plant cells obtained using such methods, to plants derived from such cells, to the progeny of such plants and to seeds derived from such plants. In such plant cells or plants, the alteration of the gene expression of a particular viral

gene is more effective, selective and more predictable than the alteration of the gene expression of a particular viral gene obtained using current methods known in the art.

The invention therefore provides:

A method comprising introducing into a cell a plurality of sub-sequences, e.g. RNA fragments or DNA sequences, characterized in that at least two of the sub-sequences have sense and antisense sequences of viral RNAs and are capable of forming a double-stranded RNA molecule. Preferably, the method comprises introducing into a cell an RNA which consists of a plurality of sub-sequences characterized in that at least two of the sub-sequences have the sequences of viral RNAs. Preferably, the RNA contains at least one translational stop codon located upstream of the 3' terminal sub-sequence. In another preferred embodiment, the method comprises introducing into a cell a nucleotide sequence or DNA molecule encoding expression of said RNA.

The invention therefore provides:

A method comprising introducing into a cell a sense RNA fragment of a viral target gene and an antisense RNA fragment of said target gene, wherein said sense RNA fragment and said antisense RNA fragment are capable of forming a double-stranded RNA molecule, wherein the expression of said target gene in said cell is altered. In a preferred embodiment, the target gene comprises a viral genome or a portion thereof and the cell is preferably resistant or tolerant to viruses. In a preferred embodiment, the virus is selected from the group consisting of tospoviruses, potyviruses, potexviruses, tobamoviruses, luteoviruses, cucumoviruses, bromoviruses, closteroviruses, tombusviruses and furoviruses. In another preferred embodiment, the RNA fragments comprise nucleotide sequences derived from a viral coat protein gene, a viral nucleocapsid protein gene, a viral replicase gene, a movement protein gene or portions thereof. In a further preferred embodiment, a cell is a plant cell, such as a monocotyledonous or a dicotyledonous cell. In another preferred embodiment, the RNA fragments are comprised in two different RNA molecules. In another preferred embodiment, the RNA fragments are mixed before being introduced into said cell. In another preferred embodiment, the RNA fragments are mixed before being introduced into said cell under conditions allowing them to form a double-stranded RNA molecule. In another preferred embodiment, the RNA fragments are introduced into said cell sequentially. In yet another preferred embodiment, the RNA fragments are comprised in

one RNA molecule. In such case, the RNA molecule is preferably capable of folding such that said RNA fragments comprised therein form a double-stranded RNA molecule.

The invention further provides:

A method comprising introducing into a cell a first DNA sequence capable of expressing in said cell a sense RNA fragment of a viral target gene, and a second DNA sequence capable of expressing in said cell an antisense RNA fragment of said target gene, wherein said sense RNA fragment and said antisense RNA fragment are capable of forming a double-stranded RNA molecule, wherein the expression of said viral target gene in said cell is altered. In a preferred embodiment, the target gene comprises a viral genome or a portion thereof and the cell is preferably resistant or tolerant to viruses. In a preferred embodiment, the virus is selected from the group consisting of tospoviruses, potyviruses, potexviruses, tobamoviruses, luteoviruses, cucumoviruses, bromoviruses, closteroviruses, tombusviruses and furoviruses. In another preferred embodiment, the DNA sequences comprises a nucleotide sequence derived from a viral coat protein gene, a viral nucleocapsid protein gene, a viral replicase gene, a movement protein gene or portions thereof. In a further preferred embodiment, a cell is a plant cell, such as a monocotyledonous or a dicotyledonous cell. In a preferred embodiment, the DNA sequences are stably integrated in the genome of the plant cell. In a preferred embodiment, the DNA molecule further comprises a promoter operably linked to said first or said second DNA sequence. In another preferred embodiment, the first DNA sequence and the second DNA sequence are comprised in two different, i.e. separate DNA molecules.

Alternatively, the first DNA sequence and the second DNA sequence are comprised in one DNA molecule. In this case, the first DNA sequence and the second DNA sequence are preferably comprised in the same DNA strand of said DNA molecule meaning that the sense RNA fragment and the antisense RNA fragment are comprised in one RNA molecule. Preferably, the RNA molecule is capable of folding such that said RNA fragments comprised therein form a double-stranded region. Examples of such RNA molecules comprise the inverted repeat sequence of SEQ ID NO: 13, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 25 or SEQ ID NO: 28. In another preferred embodiment, the sense RNA fragment and the antisense RNA fragment are comprised in or expressed as two RNA molecules. In this case, the first DNA sequence and the second DNA sequence are preferably operably linked to a bi-directional promoter or, alternatively, the first DNA

sequence is operably linked to a first promoter and the second DNA sequence is operably linked to a second promoter, wherein the first promoter and the second promoter are the same promoter or different promoters. In another preferred embodiment, the first DNA sequence and the second DNA sequence are comprised in complementary strands of said DNA molecule.

In yet another preferred embodiment, the first DNA sequence is the complementary DNA strand of the second DNA sequence in said DNA molecule. In this case, the DNA molecule further comprises a first promoter operably linked to said first or second DNA sequence. In a preferred embodiment, the DNA molecule further comprises a first site-specific recombination site between said first promoter and said first or second DNA sequence and a second site-specific recombination site at the 3'-end of said first DNA sequence, wherein said first and second site-specific recombination sites are capable of inverting said first or second DNA sequence between said first and second site-specific recombination sites in presence of a site-specific recombinase. In a further preferred embodiment and as a result of said inverting said first promoter is capable of expressing said second (or first, depending on which DNA sequence was originally linked to the promoter) DNA sequence. The plant cell preferably further comprises a site-specific recombinase capable of recognizing said site-specific recombination sites.

In yet another preferred embodiment, the DNA molecule further comprises a first promoter operably linked to said first DNA sequence and a second promoter operably linked to said second DNA sequence, wherein the first promoter and the second promoter comprise the same promoter or comprise different promoters.

In another preferred embodiment, the promoter in the DNA molecule comprises a native promoter of said cell. In a further preferred embodiment, the promoter is a heterologous promoter, for example a tissue specific promoter, a developmentally regulated promoter, a constitutive promoter or an inducible promoter. Optionally, the promoter is a divergent or bi-directional promoter capable of initiating transcription of DNA sequences on each side of the promoter.

In yet another preferred embodiment, the DNA sequence further comprises a linker between the DNA sequences encoding the sense and antisense RNA fragments. The linker comprises, e.g. an expression cassette comprising a functional gene, e.g. a selectable marker gene or regulatory sequences, e.g. intron processing signals.

The invention also further provides:

A cell comprising the sense and antisense RNA fragments of the present invention, wherein the expression of said viral target gene in said cell is altered by said RNA fragments. In a preferred embodiment, the cell is resistant or tolerant to viruses. In a preferred embodiment, the cell is a plant cell and the invention further provides a plant and the progeny thereof derived from the plant cell, and seeds derived from the plant.

The invention also provides:

DNA constructs comprising the DNA sequences of the present invention.

In a preferred embodiment, such a DNA construct comprises a first DNA sequence capable of expressing in a cell a sense RNA fragment of a viral genome or portion thereof and a second DNA sequence capable of expressing in said cell an antisense RNA fragment of said viral genome or portion thereof, wherein said sense RNA fragment and said antisense RNA fragment are capable of forming a double-stranded RNA molecule. In another preferred embodiment, the expression of said viral genome or portion thereof in said cell is altered. In another preferred embodiment, the cell is a plant cell. In another preferred embodiment, the virus is selected from the group consisting of tospoviruses, potyviruses, potexviruses, tobamoviruses, luteoviruses, cucumoviruses, bromoviruses, closteroviruses, tombusviruses and furoviruses. In another preferred embodiment, the DNA sequences comprises a nucleotide sequence derived from a viral coat protein gene, a viral nucleocapsid protein gene, a viral replicase gene, a movement protein gene or portions thereof. In yet another preferred embodiment, the DNA construct further comprises a promoter operably linked to said first or said second DNA sequence. In yet another preferred embodiment, the DNA construct comprises a first promoter operably linked to said first DNA sequence and a second promoter operably linked to said second DNA sequence. In yet another preferred embodiment, the DNA construct further comprises a bi-directional promoter operably linked to said first DNA sequence and said second DNA sequence.

The invention further provides:

A DNA construct comprising:

(a) a first DNA sequence capable of expressing in a cell a sense RNA fragment of a target gene and a second DNA sequence capable of expressing in said cell an antisense RNA fragment of said target gene, wherein said sense RNA fragment and said antisense RNA fragment are capable of forming a double-stranded RNA molecule, wherein said first DNA

sequence is the complementary strands of said second DNA sequence in said DNA construct,

- (b) a promoter operably linked to said first or second DNA sequence,
- (c) a first site-specific recombination site between said promoter and said first or second DNA sequence, and
- (d) a second site-specific recombination site at the 3'-end of said first or second DNA sequence, wherein said first and second site-specific recombination sites are capable of inverting said first or second DNA sequence between said first and second site-specific recombination sites in presence of a site-specific recombinase.

In a preferred embodiment, the expression of said target gene in said cell is altered.

The invention further provides:

A DNA construct comprising:

- (a) a first DNA sequence capable of expressing in a cell a sense RNA fragment of a target gene and a second DNA sequence capable of expressing in said cell an antisense RNA fragment of said target gene, wherein said sense RNA fragment and said antisense RNA fragment are capable of forming a double-stranded RNA molecule, wherein said first DNA sequence is the complementary strands of said second DNA sequence in said DNA construct,
- (b) a first promoter operably linked to said first DNA sequence,
- (c) a second promoter operably linked to said second DNA sequence.

In a preferred embodiment, the expression of said target gene in said cell is altered.

A "double-stranded RNA (dsRNA)" molecule comprises a sense RNA fragment of a target gene and an antisense RNA fragment of the same target gene, which both comprise nucleotide sequences complementary to one another, thereby allowing the sense and antisense RNA fragments to pair and form a double-stranded RNA molecule.

"Complementary" refers to two nucleotide sequences which comprise antiparallel nucleotide sequences capable of pairing with one another upon formation of hydrogen bonds between the complementary base residues in the antiparallel nucleotide sequences.



"Antiparallel" refers herein to two nucleotide sequences paired through hydrogen bonds between complementary base residues with phosphodiester bonds running in the 5'-3' direction in one nucleotide sequence and in the 3'-5' direction in the other nucleotide sequence.

A "target gene" is any viral gene of known function or is a gene whose function is unknown, but whose total or partial nucleotide sequence is known. A target gene is a native gene of the cell or is a heterologous gene which had previously been introduced into the cell, preferably by genetic transformation or viral infection of the cell. Preferably, the target gene is a gene in a plant cell.

A "native" gene refers to a gene which is present in the genome of the untransformed cell.

An "essential" gene is a gene encoding a protein such as e.g. a biosynthetic enzyme, receptor, signal transduction protein, structural gene product, or transport protein that is essential to the growth or survival of the cell.

To "alter" the expression of a target gene in a cell means that the level of expression of the target gene in a cell after applying the method of the present invention is different from its expression in the cell without applying the method. To alter gene expression preferably means that the expression of the target gene in the cell is reduced, preferably strongly reduced, more preferably the expression of the gene is not detectable, resulting in a knockout mutant phenotype in cells or plants or animals derived thereof.

"Isolated" is, in the context of the present invention, an isolated nucleic acid molecule that, by the hand of man, exists apart from its native environment and is therefore not a product of nature. An isolated nucleic acid molecule may exist in a purified form or may exist in a non-native environment such as, for example, a transgenic host cell.

"Expression cassette" as used herein means a DNA sequence capable of directing expression of a particular nucleotide sequence in an appropriate host cell, comprising a promoter operably linked to the nucleotide sequence of interest which is operably linked to termination signals. It also typically comprises sequences required for proper translation of the nucleotide sequence. The coding region usually codes for a protein of interest but may

also code for a functional RNA of interest, for example antisense RNA or a nontranslated RNA, in the sense or antisense direction. The expression cassette comprising the nucleotide sequence of interest may be chimeric, meaning that at least one of its components is heterologous with respect to at least one of its other components. The expression cassette may also be one which is naturally occurring but has been obtained in a recombinant form useful for heterologous expression. Typically, however, the expression cassette is heterologous with respect to the host, i.e., the particular DNA sequence of the expression cassette does not occur naturally in the host cell and must have been introduced into the host cell or an ancestor of the host cell by a transformation event. The expression of the nucleotide sequence in the expression cassette may be under the control of a constitutive promoter or of an inducible promoter which initiates transcription only when the host cell is exposed to some particular external stimulus. In the case of a multicellular organism, such as a plant, the promoter can also be specific to a particular tissue or organ or stage of development.

"Heterologous" as used herein means "of different natural origin" or represents a non-natural state. For example, if a host cell is transformed with a nucleic acid sequence derived from another organism, particularly from another species, that nucleic acid sequence is heterologous with respect to that host cell and also with respect to descendants of the host cell which carry that nucleic acid sequence. Similarly, heterologous refers to a nucleotide sequence derived from and inserted into the same natural, original cell type, but which is present in a non-natural state, e.g. a different copy number, or under the control of different regulatory elements.

In its broadest sense, the term "substantially similar", when used herein with respect to a nucleotide sequence, means a nucleotide sequence corresponding to a reference nucleotide sequence, wherein the corresponding sequence encodes a polypeptide having substantially the same structure and function as the polypeptide encoded by the reference nucleotide sequence, e.g. where only changes in amino acids not affecting the polypeptide function occur. Desirably the substantially similar nucleotide sequence encodes the polypeptide encoded by the reference nucleotide sequence. The percentage of identity between the substantially similar nucleotide sequence and the reference nucleotide sequence (number of complementary bases in the complementary sequence divided by total number of bases in the complementary sequence) desirably is at least 80%, more

desirably 85%, preferably at least 90%, more preferably at least 95%, still more preferably at least 99%.

"Regulatory elements" refer to sequences involved in conferring the expression of a nucleotide sequence. Regulatory elements comprise a promoter operably linked to the nucleotide sequence of interest and termination signals. They also typically encompass sequences required for proper translation of the nucleotide sequence.

A "plant" refers to any plant or part of a plant at any stage of development. Therein are also included cuttings, cell or tissue cultures and seeds. As used in conjunction with the present invention, the term "plant tissue" includes, but is not limited to, whole plants, plant cells, plant organs, plant seeds, protoplasts, callus, cell cultures, and any groups of plant cells organized into structural and/or functional units.

"Virus resistance or tolerance" means herein that a resistant or tolerant cell, plant or animal is either not susceptible or has reduced susceptibility to one or more viruses as compared to a sensitive cell, plant or animal. Resistance or tolerance for instance means that the usual symptoms of a virus infection are absent or reduced, or that accumulation or replication of the virus in the cell is prevented or reduced, or that movement of the virus, e.g. from cell to cell is prevented or reduced.

By "alteration of the expression of the viral genome or of a portion thereof" is typically understood that accumulation, replication or movement of the virus or a portion or component thereof, e.g. a RNA, DNA or protein of the virus, in the cell is affected.

The present invention relates to methods to regulate, i.e. alter the expression of a viral gene in cells, plants or animals. Commonly available methods to regulate the expression of a gene in cells, plants or animals lack predictability and show variability depending upon which gene is to be regulated. The present method alleviates these problems and provides for reproducible and efficacious regulation of a gene in cells, plants or animals.

The gene the expression of which is regulated is a viral genome or a portion thereof. In a preferred embodiment, a cell is an eukaryotic cell, more preferably a plant cell, such as a

monocotyledonous or a dicotyledonous cell, or an animal cell e.g. from a mammal, e.g. a human, a bovine, an ovine, a porcine, a feline or a canine, or from an avian.

The present invention utilizes a sense RNA fragment and an antisense RNA fragment of a viral target gene to alter the expression of the gene in a cell. In a first embodiment, the invention provides a method comprising introducing into a cell a sense RNA fragment of a target gene and an antisense RNA fragment of said target gene, wherein said sense RNA fragment and said antisense RNA fragment are capable of forming a double-stranded RNA molecule, wherein the expression of said target gene in said cell is altered. The RNA fragments are introduced in the cells by different transformation methods such as particle bombardment or PEG-mediated transformation or electroporation. In another preferred embodiment, other techniques, such as microinjection of the RNA fragments, are used. In a preferred embodiment, the RNA fragments are comprised in two different RNA molecules. In this case, the RNA fragments are mixed before being introduced into said cell, e.g. under conditions allowing them to form a double-stranded RNA molecule. In another preferred embodiment, the RNA fragments are introduced into said cell sequentially. Preferably, the time interval between the introduction of each of the RNA molecules is short, preferably less than one hour. In yet another embodiment, the RNA fragments are comprised in one RNA molecule. By using one single RNA molecule the two complementary RNA fragments are in close proximity such that pairing and is favored. In such case, the RNA molecule is preferably capable of folding such that said RNA fragments comprised therein form a double-stranded region. In this case, the complementary parts of the RNA fragments recognize one another, pair with each other and form the double-stranded RNA molecule. In a preferred embodiment, the RNA fragments are incubated under conditions allowing them to form a double-stranded RNA molecule prior to introduction into the cell. In yet another embodiment, the RNA molecule comprises a linker between the sense RNA fragment and the antisense RNA fragment. The linker preferably comprises a RNA sequence encoded by an expression cassette comprising a functional gene, e.g. a selectable marker gene. In another embodiment, the linker comprises a RNA sequence encoded by regulatory sequences, which e.g. comprise intron processing signals. In a further embodiment, the present invention provides a method of altering the expression of a viral genome comprising introducing into a cell a first DNA sequence capable of expressing in said cell a sense RNA fragment of said viral genome and a second DNA sequence capable of expressing in said cell an antisense RNA fragment of said viral genome, wherein said sense RNA fragment and said antisense RNA fragment are capable

of forming a double-stranded RNA molecule. In a preferred embodiment, the first DNA sequence and the second DNA sequence are stably integrated in the genome of the cell. In another preferred embodiment, the DNA sequences are comprised in two different DNA molecules. In another preferred embodiment, the DNA sequences are comprised in one DNA molecule. In such case, the DNA molecule preferably encodes a single RNA molecule which comprises the sense and antisense RNA fragments. By using one single RNA molecule the two complementary RNA fragments are in close proximity such that pairing and is favored. The DNA molecule encodes two separate RNA molecules, e.g. one RNA molecule comprising a sense RNA fragment and one RNA molecule comprising an antisense RNA fragment. The single RNA molecule or the two distinct RNA molecules are preferably capable of folding such that said RNA fragments comprised therein form a double-stranded region, in which the complementary parts of the RNA fragments recognize one another, pair with each other and form the double-stranded RNA molecule.

In one embodiment, the single DNA molecule or each of the two distinct DNA molecules comprises a promoter operably linked to said DNA sequences. In a preferred embodiment, the promoter in the DNA sequence comprises a native plant promoter or the natural promoter of said viral gene to be inactivated, in order to insure that the double-stranded RNA is expressed in the same tissues and at the same time in development as the viral target gene. In another embodiment the promoter is a heterologous promoter, for example a tissue specific promoter, a developmentally regulated promoter, a constitutive promoter or an inducible promoter.

In yet another embodiment, the DNA sequence comprises a linker between the DNA sequences encoding said two complementary RNA fragments. The linker preferably comprises an expression cassette comprising a functional gene, e.g. a selectable marker gene. In another embodiment, the linker comprises regulatory sequences, which e.g. comprise intron processing signals.

DNA molecules of the present invention are transformed into cells using methods well-known in the art or described below. The present invention also provides a DNA construct comprising DNA sequences of the present invention, a recombinant vector comprising such DNA constructs and a composition comprising DNA sequences of the present invention.

In the present invention the complementary region between the sense and antisense RNA fragments is desirably at least 15 nucleotides long, more desirably at least 50 nucleotides long, and preferably at least 500 bp long. Preferably, the complementary region is less than 5 kb and more preferably less than 2 kb. In one particular embodiment the complementary

region between the sense and antisense RNA fragments comprises the coding region of the target gene. In another preferred embodiment, the complementary region comprises untranslated regions (UTR) of the target gene, e.g. 5' UTR or 3' UTR. In yet another preferred embodiment, a DNA sequence encoding a sense or antisense RNA fragment of the present invention is derived from a c-DNA molecule or comprises regulatory elements of the viral target gene whose expression is to be altered, such as promoter or termination signals.

In another preferred embodiment, the complementary region between the sense and antisense RNA fragments is identical to the corresponding sequence of the gene whose expression is altered. In another preferred embodiment, the complementary region between the sense and antisense RNA fragments is substantially similar to the corresponding sequence of the gene whose expression is altered and is still capable of altering the expression of the gene. In this case, the complementary region is desirably at least 50% identical to the corresponding sequence of the gene whose expression is altered more desirably at least 70% identical, preferably at least 90% identical, more preferably at least 95% identical. Thereby, using a single double-stranded RNA molecule allows to alter the expression of a single gene or of a plurality of genes, the single gene comprising sequences identical to the double-stranded RNA or being substantially similar to the double-stranded RNA.

In another preferred embodiment, the complementary region between the sense and antisense RNA fragments does not contain any mismatch between the sense and antisense RNA fragments. In another preferred embodiment, the complementary region between the sense and antisense RNA fragments comprises at least one mismatch between the sense and antisense RNA fragments, and the two RNA fragments are still capable of pairing and forming a double-stranded RNA molecule, thereby altering the expression of the gene.

Desirably, there is less than 50% mismatch between the sense and antisense RNA fragments in the complementary region, more desirably less than 30% mismatch, preferably less than 20% mismatch, more preferably less than 10% mismatch, yet more preferably less than 5 % mismatch.

#### Resistance or Tolerance to Viruses

The present invention results in cells, animals or plants which are virus resistant or tolerant. Viruses controlled using the present invention comprise but are not limited to dsDNA viruses, dsRNA viruses, plus-strand and minus-strand ssRNA viruses, ambisense RNA

viruses and retroviruses. Preferably controlled are plant viruses, such as astroviruses (e.g. tomato spotted wilt virus abbreviated TSWV), potyviruses (e.g. turnip mosaic virus abbreviated TuMV, lettuce mosaic virus abbreviated LMV, water melon mosaic virus II abbreviated WMVII, Zucchini yellow mosaic virus abbreviated ZYMV, potato virus Y abbreviated PVY, and papaya ringspot virus abbreviated PRSV), potexviruses, tobamoviruses (e.g. pepper mild mottle virus abbreviated PMMV, and tomato mosaic virus abbreviated ToMV), luteoviruses (e.g. beet western yellows virus abbreviated BWYV, and beet mild yellowing virus abbreviated BMV), cucumoviruses (e.g. cucumber mosaic virus abbreviated CMV), geminiviruses (e.g. tomato yellow leafcurl virus abbreviated TYLCV), caulimoviruses (e.g. Cauliflower mosaic virus abbreviated CaMV), bromoviruses, closteroviruses, tombusviruses and furoviruses (e.g. beet necrotic yellow vein virus abbreviated BNYYV). Additional classes of viruses which can be controlled using the present invention are described in Zacher et al. (1995) *Journal of General Virology*, 76: 231-247 and in Martelli (1992) *Plant Disease*, 76: 436-441. Preferred DNA sequences of a viral genome to achieve virus control correspond to regions of the genes encoding viral coat proteins, viral nucleocapsid proteins, viral replicases, movement proteins and the like. Further nucleotide sequences useful to control virus genome expression are described in WO 95/09920. Preferred DNA sequences may include portions of the viral genome not translated into proteins, e.g. 5' or 3' untranslated regions.

Preferably, a method of the present invention leads to resistance or tolerance to a broad-spectrum of viruses. For example, a method of the present invention leads to resistance or tolerance to the virus encoded by the viral genome and other viruses in the same virus class, group or genus. Alternatively, a method of the present invention leads to resistance or tolerance to the virus encoded by the viral genome and other isolates of the same virus. Also, a method of the present invention leads to resistance or tolerance to the virus encoded by the viral genome and other viruses in the same virus group or genus in different species, preferably in related species, preferably species in which such viruses exist. Optionally, more than one pair, i.e. at least two pairs of sense and antisense RNA fragments which are capable of forming a dsRNA are used. Such pairs are for example derived from the same viral genome, but from different portions of the same viral genome. Alternatively, such pairs are derived from different viral genomes. Thus, resistance or tolerance to different virus classes, groups or genera is achieved using the present invention.

Plant cells and plants derived thereof, which are virus resistant or tolerant are preferably dicotyledonous plants. Methods to confer resistance or tolerance to furoviruses (see e.g. Rush and Heidel (1995) Plant Disease 79: 868-875) in sugar beet and canola are disclosed in the present invention and described in further detail for BNYVV, the causal agent of rhizomania (crazy roots) in sugar-beet, in Example 9. Methods to confer resistance or tolerance to "virus yellow" (see e.g. CRC Handbook on Disease of Sugar Beet, Volume II, pp. 35-52) such as BMV and beet western yellows virus (BWYV) that infect sugar beet and oilseed rape, respectively, are described in further detail in Example 8. Methods of the present invention also confer tolerance or resistance to viruses in monocotyledonous plants. For example, using the teachings of the present invention and of US patent 5,569,828 tolerance or resistance to Maize chlorotic dwarf virus is obtained. Similarly, using the teachings of the present invention and of US patent 5,428,144 tolerance or resistance to Maize dwarf mosaic virus is achieved.

#### Plant Transformation Technology

DNA molecules of the present invention are incorporated in plant or bacterial cells using conventional recombinant DNA technology. Generally, a DNA molecule of the present invention is comprised in a transformation vector. A large number of such vector systems known in the art are used, such as plasmids, bacteriophage viruses and other modified viruses. The components of the expression system are also modified, e.g. to increase expression of the sense and antisense RNA fragments. For example, truncated sequences, nucleotide substitutions or other modifications are employed. Expression systems known in the art are used to transform virtually any crop plant cell under suitable conditions. A transgene comprising a DNA molecule of the present invention is preferably stably transformed and integrated into the genome of the host cells. In another preferred embodiment, the transgene comprising a DNA molecule of the present invention is located on a self-replicating vector. Examples of self-replicating vectors are viruses, in particular gemini viruses. Transformed cells are preferably regenerated into whole plants.

Plants transformed in accordance with the present invention may be monocots or dicots and include, but are not limited to, maize, wheat, barley, rye, sweet potato, bean, pea, chicory, lettuce, cabbage, cauliflower, broccoli, turnip, radish, spinach, asparagus, onion, garlic, pepper, celery, squash, pumpkin, hemp, zucchini, apple, pear, quince, melon, plum, cherry, peach, nectarine, apricot, strawberry, grape, raspberry, blackberry, pineapple, avocado, papaya, mango, banana, soybean, tomato, sorghum, sugarcane, sugarbeet, sunflower,



rapeseed, clover, tobacco, carrot, cotton, alfalfa, rice, potato, eggplant, cucumber, *Arabidopsis*, and woody plants such as coniferous and deciduous trees. Once a desired nucleotide sequence has been transformed into a particular plant species, it may be propagated in that species or moved into other varieties of the same species, particularly including commercial varieties, using traditional breeding techniques.

#### A. Requirements for Construction of Plant Expression Cassettes

Gene sequences intended for expression in transgenic plants are first assembled in expression cassettes behind a suitable promoter expressible in plants. The expression cassettes may also comprise any further sequences required or selected for the expression of the transgene. Such sequences include e.g., but are not restricted to, transcription terminators, extraneous sequences to enhance expression such as introns, vital sequences, and sequences intended for the targeting of the gene product to specific organelles and cell compartments. These expression cassettes can then be easily transferred to the plant transformation vectors described *infra*. The following is a description of various components of typical expression cassettes.

##### 1. Promoters

The selection of the promoter used in expression cassettes determine the spatial and temporal expression pattern of the transgene in the transgenic plant. Selected promoters express transgenes in specific cell types (such as leaf epidermal cells, mesophyll cells, root cortex cells) or in specific tissues or organs (roots, leaves or flowers, for example) and the selection reflects the desired location of accumulation of the gene product. Alternatively, the selected promoter drives expression of the gene under various inducing conditions. Promoters vary in their strength, i.e., ability to promote transcription. Depending upon the host cell system utilized, any one of a number of suitable promoters known in the art is used. For example, for constitutive expression, the CaMV 35S promoter, the rice actin promoter, or the ubiquitin promoter are used. For example, for regulatable expression, the chemically inducible PR-1 promoter from tobacco or *Arabidopsis* is used (*see, e.g.*, U.S. Patent No. 5,689,044).

A preferred category of promoters is that which is wound inducible. Numerous promoters have been described which are expressed at wound sites. Preferred promoters of this kind include those described by Stanford *et al.* Mol. Gen. Genet. 215: 200-208 (1989), Xu *et al.* Plant Molec. Biol. 22: 573-588 (1993), Logemann *et al.* Plant Cell 1: 151-158 (1989),

Rohrmeier & Lehle, *Plant Molec. Biol.* 22: 783-792 (1993), Firek *et al.* *Plant Molec. Biol.* 22: 129-142 (1993), and Warner *et al.* *Plant J.* 3: 191-201 (1993).

Preferred tissue specific expression patterns include green tissue specific, root specific, stem specific, and flower specific. Promoters suitable for expression in green tissue include many which regulate genes involved in photosynthesis, and many of these have been cloned from both monocotyledons and dicotyledons. A preferred promoter is the maize PEPC promoter from the phosphoenol carboxylase gene (Hudspeth & Grula, *Plant Molec. Biol.* 12: 579-589 (1989)). A preferred promoter for root specific expression is that described by de Framond (*FEBS* 290: 103-106 (1991); EP 0 452 269 and a further preferred root-specific promoter is that from the T-1 gene provided by this invention. A preferred stem specific promoter is that described in US patent 5,625,136 and which drives expression of the maize *trpA* gene.

Preferred embodiments of the invention are transgenic plants expressing nucleotide sequence in a root-specific fashion. Further preferred embodiments are transgenic plants expressing the nucleotide sequence in a wound-inducible or pathogen infection-inducible manner.

## 2. Transcriptional Terminators

A variety of transcriptional terminators are available for use in expression cassettes. These are responsible for the termination of transcription beyond the transgene and its correct polyadenylation. Appropriate transcriptional terminators are those that are known to function in plants and include the CaMV 35S terminator, the *tml* terminator, the nopaline synthase terminator and the pea *rbcS* E9 terminator. These are used in both monocotyledonous and dicotyledonous plants.

## 3. Sequences for the Enhancement or Regulation of Expression

Numerous sequences have been found to enhance gene expression from within the transcriptional unit and these sequences can be used in conjunction with the genes of this invention to increase their expression in transgenic plants. For example, various intron sequences such as introns of the maize *Adhl* gene have been shown to enhance expression, particularly in monocotyledonous cells. In addition, a number of non-translated leader sequences derived from viruses are also known to enhance expression, and these are particularly effective in dicotyledonous cells.

#### 4. Coding Sequence Optimization

The coding sequence of the selected gene may be genetically engineered by altering the coding sequence for optimal expression in the crop species of interest. Methods for modifying coding sequences to achieve optimal expression in a particular crop species are well known (see, e.g. Perlak *et al.*, *Proc. Natl. Acad. Sci. USA* 88: 3324 (1991); and Koziel *et al.*, *Bio/technol.* 11: 194 (1993)).

In another preferred embodiment, a DNA molecule of the present invention is directly transformed into the plastid genome. Plastid transformation technology is extensively described in U.S. Patent Nos. 5,451,513, 5,545,817, and 5,545,818, in PCT application no. WO 95/16783, and in McBride *et al.* (1994) *Proc. Natl. Acad. Sci. USA* 91, 7301-7305. The basic technique for chloroplast transformation involves introducing regions of cloned plastid DNA flanking a selectable marker together with the gene of interest into a suitable target tissue, e.g., using biolistics or protoplast transformation (e.g., calcium chloride or PEG mediated transformation). The 1 to 1.5 kb flanking regions, termed targeting sequences, facilitate homologous recombination with the plastid genome and thus allow the replacement or modification of specific regions of the plastome. Initially, point mutations in the chloroplast 16S rRNA and rps12 genes conferring resistance to spectinomycin and/or streptomycin are utilized as selectable markers for transformation (Svab, Z., Hajdukiewicz, P., and Maliga, P. (1990) *Proc. Natl. Acad. Sci. USA* 87, 8526-8530; Staub, J. M., and Maliga, P. (1992) *Plant Cell* 4, 39-45). The presence of cloning sites between these markers allowed creation of a plastid targeting vector for introduction of foreign DNA molecules (Staub, J.M., and Maliga, P. (1993) *EMBO J.* 12, 601-606). Substantial increases in transformation frequency are obtained by replacement of the recessive rRNA or r-protein antibiotic resistance genes with a dominant selectable marker, the bacterial *aadA* gene encoding the spectinomycin-detoxifying enzyme aminoglycoside-3'-adenyltransferase (Svab, Z., and Maliga, P. (1993) *Proc. Natl. Acad. Sci. USA* 90, 913-917). Previously, this marker had been used successfully for high-frequency transformation of the plastid genome of the green alga *Chlamydomonas reinhardtii* (Goldschmidt-Clermont, M. (1991) *Nucl. Acids Res.* 19: 4083-4089). Other selectable markers useful for plastid transformation are known in the art and encompassed within the scope of the invention.

Plastid expression, in which genes are inserted by homologous recombination into the several thousand copies of the circular plastid genome present in each plant cell. In a preferred embodiment, a DNA of the present invention is inserted into a plastid targeting vector and transformed into the plastid genome of a desired plant host. Plants homoplasmic

for plastid genomes containing the DNA molecule of the present invention are obtained, and are preferentially capable of high expression of the DNA molecule. Preferably, sense and antisense RNA fragments encoded by the DNA molecule are capable of pairing and of forming a double-stranded RNA molecules in plant plastids to alter the expression of plastid genes. In a preferred embodiment, the sense and antisense fragments do not comprise any mismatch in the complementary region. In another preferred embodiment, the sense and antisense fragments comprise at least one mismatch in the complementary region. In this case, the DNA sequences in the DNA molecule encoding the RNA fragments are not capable of recombining with each other.

#### B. Construction of Plant Transformation Vectors

Numerous transformation vectors available for plant transformation are known to those of ordinary skill in the plant transformation arts, and the genes pertinent to this invention can be used in conjunction with any such vectors. The selection of vector depends upon the preferred transformation technique and the target species for transformation. For certain target species, different antibiotic or herbicide selection markers are preferred. Selection markers used routinely in transformation include the *nptII* gene, which confers resistance to kanamycin and related antibiotics (Messing & Vierra. *Gene* 19: 259-268 (1982); Bevan et al., *Nature* 304:184-187 (1983)), the *bar* gene, which confers resistance to the herbicide phosphinothricin (White et al., *Nucl. Acids Res* 18: 1062 (1990), Spencer et al. *Theor. Appl. Genet* 79: 625-631 (1990)), the *hph* gene, which confers resistance to the antibiotic hygromycin (Blochinger & Diggelmann, *Mol Cell Biol* 4: 2929-2931), and the *dhfr* gene, which confers resistance to methatrexate (Bourouis et al., *EMBO J.* 2(7): 1099-1104 (1983)), and the EPSPS gene, which confers resistance to glyphosate (U.S. Patent Nos. 4,940,935 and 5,188,642).

##### 1. Vectors Suitable for *Agrobacterium* Transformation

Many vectors are available for transformation using *Agrobacterium tumefaciens*. These typically carry at least one T-DNA border sequence and include vectors such as pBIN19 (Bevan, *Nucl. Acids Res.* (1984)) and pXYZ. Typical vectors suitable for *Agrobacterium* transformation include the binary vectors pCIB200 and pCIB2001, as well as the binary vector pCIB10 and hygromycin selection derivatives thereof. (See, for example, U.S. Patent No. 5,639,949).

## 2. Vectors Suitable for non-*Agrobacterium* Transformation

Transformation without the use of *Agrobacterium tumefaciens* circumvents the requirement for T-DNA sequences in the chosen transformation vector and consequently vectors lacking these sequences are utilized in addition to vectors such as the ones described above which contain T-DNA sequences. Transformation techniques that do not rely on *Agrobacterium* include transformation via particle bombardment, protoplast uptake (e.g. PEG and electroporation) and microinjection. The choice of vector depends largely on the preferred selection for the species being transformed. Typical vectors suitable for non-*Agrobacterium* transformation include pCIB3064, pSOG19, and pSOG35. (See, for example, U.S. Patent No. 5,639,949).

## C. Transformation Techniques

Once the DNA sequence of interest is cloned into an expression system, it is transformed into a plant cell. Methods for transformation and regeneration of plants are well known in the art. For example, Ti plasmid vectors have been utilized for the delivery of foreign DNA, as well as direct DNA uptake, liposomes, electroporation, micro-injection, and microprojectiles. In addition, bacteria from the genus *Agrobacterium* can be utilized to transform plant cells.

Transformation techniques for dicotyledons are well known in the art and include *Agrobacterium*-based techniques and techniques that do not require *Agrobacterium*. Non-*Agrobacterium* techniques involve the uptake of exogenous genetic material directly by protoplasts or cells. This is accomplished by PEG or electroporation mediated uptake, particle bombardment-mediated delivery, or microinjection. In each case the transformed cells are regenerated to whole plants using standard techniques known in the art.

Transformation of most monocotyledon species has now also become routine. Preferred techniques include direct gene transfer into protoplasts using PEG or electroporation techniques, particle bombardment into callus tissue, as well as *Agrobacterium*-mediated transformation.

The invention will be further described by reference to the following detailed examples. These examples are provided for purposes of illustration only, and are not intended to be limiting unless otherwise specified.

**EXAMPLES**

Standard recombinant DNA and molecular cloning techniques used here are well known in the art and are described by Sambrook, *et al.*, Molecular Cloning, eds., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1989) and by T.J. Silhavy, M.L. Berman, and L.W. Enquist, Experiments with Gene Fusions, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1984) and by Ausubel, F.M. *et al.*, Current Protocols in Molecular Biology, pub. by Greene Publishing Assoc. and Wiley-Interscience (1987).

**Example 1: Regulation of the Expression of a Luciferase Gene**Construction of a chimeric DNA molecule encoding a luciferase RNA duplex

A 738 bp "sense" oriented fragment of the firefly luciferase gene from plasmid pLuc+ (Promega) is amplified from pPH108 plasmid DNA using oligonucleotide primers ds\_Luc1 (5' -CGC GGA TCC TGG AAG ACG CCA AAA ACA-3', SEQ ID NO:1; *Bam*HI restriction site underlined) and ds\_Luc2 (5' -CGG AAG CTT AGG CTC GCC TAA TCG CAG TAT CCG GAA TG-3', SEQ ID NO:2; *Hind*III restriction site underlined). TurboPfu thermostable DNA polymerase (Stratagene) is used in 50 ul reactions according to the manufacturers protocol with five cycles of 95°C / 1 min, 55°C / 1.5 min, 72°C / 2 min followed by twenty five cycles of 95°C / 1 min, 72°C / 3.5 min. In a similar manner a 737 bp "antisense" oriented fragment of the firefly luciferase gene from plasmid pLuc+ is amplified by PCR from pPH108 plasmid DNA using oligonucleotide primers ds\_Luc3 (5' -CGG TCT AGA GGA AGA CGC CAA AAA CAT A-3', SEQ ID NO:3; *Xba*I restriction site underlined) and ds\_Luc2 (5' -CGG AAG CTT AGG CTC GCC TAA TCG CAG TAT CCG GAA TG-3', SEQ ID NO: 2; *Hind*III restriction site underlined). The resulting DNA fragments are purified by electrophoresis through a 1% Tris-acetate gel made from low-melting point agarose (FMC) followed by phenol-chloroform extraction of the excised gel slices containing the PCR products. DNA from the sense product (ds\_Luc1/2) is digested with *Bam*HI and *Hind*III and DNA from the antisense product (ds\_Luc3/2) is digested with *Xba*I and *Hind*III according to standard methods (restriction enzymes were obtained from New England Biolabs). The resulting sticky-ended DNA fragments are gel purified as described above. A DNA fragment containing the *mas 1'* promoter (Velten et al. (19984) EMBO J. 3: 2723-2730) is obtained by digesting plasmid CSA104 with *Eco*RI and *Hinc*II and purifying a 564 bp DNA fragment. This fragment is redigested with *Bam*HI and the 484 bp *Eco*RI – *Bam*HI sub-

fragment containing the *mas* 1' promoter isolated and gel purified. In order to construct plasmid pPH169, DNA from cloning vector pLitmus29 (New England Biolabs) is digested with *EcoRI* and *XbaI*, and the isolated fragment is ligated in a four-way reaction using T4 DNA ligase (New England Biolabs) to the *mas* 1' promoter *EcoRI* – *BamHI* fragment and the sense (*BamHI* – *HindIII*) and antisense (*HindIII* – *XbaI*) ds\_Luc luciferase gene fragments. In order to construct binary vector pPH170 for *Agrobacterium*-mediated plant transformation with the ds\_Luc1/2/3 RNA duplex construct, DNA from binary plasmid pSGCHC1 carrying a kanamycin resistance gene for bacterial selection and a hygromycin resistance gene for transgenic plant selection is digested with *EcoRI* and *XbaI*. The resulting 11.6 kb isolated fragment from pSGCHC1 is ligated in a four-way reaction using T4 DNA ligase (New England Biolabs) to the *mas* 1' promoter *EcoRI* – *BamHI* fragment and the sense (*BamHI* – *HindIII*) and antisense (*HindIII* – *XbaI*) ds\_Luc luciferase gene fragments.

#### Transformation of *Agrobacterium* and Vacuum-infiltration of *Arabidopsis* plants

Plasmids pPH170 is introduced into *Agrobacterium tumefaciens* GV3101 by electroporation and transformed colonies selected and amplified. Four to five week old plants of *Arabidopsis thaliana* mutant lines expressing luciferase either constitutively (UBQ3 promoter (Norris et al. (1993) PMB 21: 895-906) / UBQ3 + CaMV 35S 5' UTR/luc+; *pPH108*) or inducibly (*Arabidopsis* PR-1 promoter/luc+; *pPH135*, line 6E) are vacuum infiltrated with *Agrobacterium* clones carrying the pPH170 binary T-DNA vector. Transformed plants are co-selected on hygromycin and kanamycin and grown under controlled phytotron conditions for determination of luciferase activity. In addition, luciferase activity in the *pPH135*-6E background is assessed 48 hr after induction with BTH (BTH treatment essentially as described in Lawton et al. Plant J. 10: 71-82). Luciferase activity is quantified using a luminescence-based assay in tissue extracts following the addition of luciferin substrate. Luciferase activity is also monitored *in planta* using a CCD-cooled video imaging system (Hamamatsu).

#### **Example 2: Regulation of the Expression of the *Arabidopsis* GL1 Gene**

The GL1 gene encodes a *myb*-like transcription factor that is required for initiation of normal trichome (leaf hair) formation (Oppenheimer et al. (1991) Cell 67: 483-493). Knock out of GL1 expression early in development results in plants lacking trichomes. The knockout phenotype is easy to identify in young seedlings and is not lethal. Three vectors for constitutive expression and three vectors for Gal4CI-regulated expression are constructed.

The three different vectors to test for each promoter are sense (+) expression, antisense (-) expression, and duplex (+/-) RNA expression of a GL1 gene fragment. The (+) and (-) vectors are controls to compare for their effect on expression of GL1. In each case a 5' fragment from bases #739 to #1781 of the GL1 sequence (GenBank Accession M79448) are used for vector construction.

#### Gal4CI-regulated Expression

The GL1 gene fragments is cloned into the crossing-inducible vector construct pJG304-1 as *NcoI*-*SacI* fragments. Plasmid pJG304 is derived from pBSSK+. Plasmid pBS SK+ (Stratagene, LaJolla, CA) is linearized with *SacI*, treated with mung bean nuclease to remove the *SacI* site, and re-ligated with T4 ligase to make pJG201. The 10XGAL4 consensus binding site/CaMV 35S minimal promoter/GUS gene/CaMV terminator cassette is removed from pAT71 with *KpnI* and cloned into the *KpnI* site of pJG201 to make pJG304. Plasmid pJG304 is partially digested with restriction endonuclease *Asp718* to isolate a full-length linear fragment. This fragment is ligated with a molar excess of the 22 base oligonucleotide JG-L (5' -GTA CCT CGA G TC TAG ACT CGA G-3', SEQ ID NO: 4). Restriction analysis is used to identify a clone with this linker inserted 5' to the GAL4 DNA binding site, and this plasmid is designated pJG304DXhoI.

The *NcoI* and *SacI* sites are added to the ends of (+) and (-) fragments by synthesizing PCR primers with the appropriate restriction sites to the 5' termini. The (+/-) GL1 fragment is produced by first producing two fragment : a (+) fragment with the *NcoI* site at the 5' terminus and a *HindIII* site at the 3' terminus and a (-) fragment with a *HindIII* site at the 5' terminus and a *SacI* site at the 3' terminus. The duplex unit is produced by ligation of the resulting fragments at the *EcoRI* site. The expression unit contains the Gal4 DNA binding domain, followed by a minimal TATA sequence, and the GL1 gene fragment oriented either (+), (-) or (+/-).

#### Constitutive Expression

The *mas 1'* promoter of mannopine synthase from *Agrobacterium*(ref), a relatively strong and constitutive in dicot plants is used. As above, the GL (+), (-), and (+/-) fragments are ligated behind the 1' promoter in pBluescript. The three different expression cassettes are ligated into pCIB200 as *EcoRI*/*Sall* fragments (Uknes et al. (1993) Plant Cell 5: 159-169).



**Example 3: Regulation of the Expression of the Cystathionine Beta Lyase Gene**

The Cystathionine Beta Lyase (CBL) Gene encodes a step in the methionine biosynthesis pathway. The effect of the regulation of its expression in plants is tested using sense and antisense constructs, and double-stranded RNA constructs.

Antisense construct: binary BASTA vector pJG261 is used containing a fragment from the pJG304DXhoI vector with an insertion of part of the CBL gene in an antisense orientation (nucleotides #13-1159, Genbank accession #L40511).

Sense construct: same as antisense construct, except the CBL fragment is in the opposite orientation. This construct contains the ATG start codon and most of the CBL ORF and serves as a control for regulation of the expression of the CBL gene.

Double-stranded RNA construct: A CBL gene fragment (#13-1159) in the sense orientation is inserted into the *SaII* site of vector pJG304-1 downstream of the antisense orientation version of the CBL gene. A linker of about 10 bp is present between the two copies of CBL.

**Example 4: Requirements for Construction of Plant Expression Cassettes**

Gene sequences intended for expression in transgenic plants are firstly assembled in expression cassettes behind a suitable promoter and upstream of a suitable transcription terminator. All requirement for constructions of plant expression cassettes apply to the DNA molecules of the present invention and are carried out using techniques well-known in the art.

**Promoter Selection**

The selection of promoter used in expression cassettes determines the spatial and temporal expression pattern of the DNA molecule in the transgenic plant. Selected promoters express DNA molecule in specific cell types (such as leaf epidermal cells, mesophyll cells, root cortex cells) or in specific tissues or organs (roots, leaves or flowers, for example) and this selection reflects the desired location of biosynthesis of a RNA fragment encoded by the DNA molecule. Alternatively, the selected promoter may drive expression of the DNA molecule under a light-induced or other temporally regulated promoter. A further alternative is that the selected promoter be chemically regulated. This provides the possibility of

inducing the expression of the DNA molecule only when desired and caused by treatment with a chemical inducer.

#### Transcriptional Terminators

A variety of transcriptional terminators are available for use in expression cassettes. These are responsible for the termination of transcription and, preferably, correct polyadenylation. Appropriate transcriptional terminators and those which are known to function in plants and include the CaMV 35S terminator, the *tm1* terminator, the nopaline synthase terminator, the pea *rbcS* E9 terminator. These can be used in both monocotyledons and dicotyledons.

#### Sequences for the Enhancement or Regulation of Expression

Numerous sequences have been found to enhance gene expression from within the transcriptional unit and these sequences can be used in conjunction with the DNA molecule of this invention to increase its expression in transgenic plants.

Various intron sequences have been shown to enhance expression, particularly in monocotyledonous cells. For example, the introns of the maize *Adh1* gene have been found to significantly enhance the expression of the wild-type gene under its cognate promoter when introduced into maize cells. Intron 1 is found to be particularly effective and enhanced expression in fusion constructs with the chloramphenicol acetyltransferase gene (Callis *et al.*, *Genes Devel* **1**: 1183-1200 (1987)). In the same experimental system, the intron from the maize *bronze1* gene had a similar effect in enhancing expression (Callis *et al.*, *supra*). Intron sequences have been routinely incorporated into plant transformation vectors, typically within the non-translated leader.

A number of non-translated leader sequences derived from viruses are also known to enhance expression, and these are particularly effective in dicotyledonous cells.

Specifically, leader sequences from Tobacco Mosaic Virus (TMV, the "Ω-sequence"), Maize Chlorotic Mottle Virus (MCMV), and Alfalfa Mosaic Virus (AMV) have been shown to be effective in enhancing expression (*e.g.* Gallie *et al.* *Nucl. Acids Res.* **15**: 8693-8711 (1987); Skuzeski *et al.* *Plant Molec. Biol.* **15**: 65-79 (1990)).

#### **Example 5: Examples of Expression Cassette Construction**

The present invention encompasses the expression of a DNA molecule of the present invention under the regulation of any promoter which is expressible in plants, regardless of the origin of the promoter. Therefore the DNA molecule is inserted into any of the

expression cassette using techniques well-known in the art. These expression cassettes can then be easily transferred to the plant transformation vectors described below. Furthermore, the invention also encompasses the use of any plant-expressible promoter in conjunction with any further sequences required or selected for the expression of the DNA molecule. Such sequences include, but are not restricted to, transcriptional terminators, extraneous sequences to enhance expression (such as introns [*e.g.* *Adh* intron 1], viral sequences [*e. g.* TMV- $\Omega$ ]).

#### Constitutive Expression: the CaMV 35S Promoter

Construction of the plasmid pCGN1761 is described in the published patent application EP 0 392 225. pCGN1761 contains the "double" 35S promoter and the *tmI* transcriptional terminator with a unique *EcoRI* site between the promoter and the terminator and has a pUC-type backbone. A derivative of pCGN1761 is constructed which has a modified polylinker which includes *NotI* and *XhoI* sites in addition to the existing *EcoRI* site. This derivative is designated pCGN1761ENX. pCGN1761ENX is useful for the cloning of cDNA sequences or gene sequences (including microbial ORF sequences) within its polylinker for the purposes of their expression under the control of the 35S promoter in transgenic plants. The entire 35S promoter-gene sequence-*tmI* terminator cassette of such a construction can be excised by *HindIII*, *SphI*, *Sall*, and *XbaI* sites 5' to the promoter and *XbaI*, *BamHI* and *BglII* sites 3' to the terminator for transfer to transformation vectors. Furthermore, the double 35S promoter fragment can be removed by 5' excision with *HindIII*, *SphI*, *Sall*, *XbaI*, or *PstI*, and 3' excision with any of the polylinker restriction sites (*EcoRI*, *NotI* or *XhoI*) for replacement with another promoter.

Accordingly, a DNA molecule of the present invention is inserted into pCGN1761ENX for constitutive expression under the control of the CaMV 35S promoter.

#### Expression under a Chemically Regulatable Promoter

This section describes the replacement of the double 35S promoter in pCGN1761ENX with any promoter of choice; by way of example the chemically regulated PR-1a promoter is described. The promoter of choice is preferably excised from its source by restriction enzymes, but can alternatively be PCR-amplified using primers which carry appropriate terminal restriction sites. Should PCR-amplification be undertaken, then the promoter should be resequenced to check for amplification errors after the cloning of the amplified promoter in the target vector. The chemically regulatable tobacco PR-1a promoter is

cleaved from plasmid pCIB1004 (see EP 0 332 104) and transferred to plasmid pCGN1761ENX. pCIB1004 is cleaved with *NcoI* and the resultant 3' overhang of the linearized fragment is rendered blunt by treatment with T4 DNA polymerase. The fragment is then cleaved with *HindIII* and the resultant PR-1a promoter containing fragment is gel purified and cloned into pCGN1761ENX from which the double 35S promoter has been removed. This is done by cleavage with *XhoI* and blunting with T4 polymerase, followed by cleavage with *HindIII* and isolation of the larger vector-terminator containing fragment into which the pCIB1004 promoter fragment is cloned. This generates a pCGN1761ENX derivative with the PR-1a promoter and the *tml* terminator and an intervening polylinker with unique *EcoRI* and *NotI* sites.

A DNA molecule of the present invention is inserted into this vector, and the fusion product (*i.e.* promoter-gene-terminator) is subsequently transferred to any selected transformation vector, including those described in this application, thus providing for chemically inducible expression of the DNA molecule.

#### Constitutive Expression: the Actin Promoter

Several isoforms of actin are known to be expressed in most cell types and consequently the actin promoter is a good choice for a constitutive promoter. In particular, the promoter from the rice *Act1* gene has been cloned and characterized (McElroy *et al.* Plant Cell 2: 163-171 (1990)). A 1.3 kb fragment of the promoter is found to contain all the regulatory elements required for expression in rice protoplasts. Furthermore, numerous expression vectors based on the *Act1* promoter have been constructed specifically for use in monocotyledons (McElroy *et al.* Mol. Gen. Genet. 231: 150-160 (1991)). These incorporate the *Act1*-intron 1, *Adh1* 5' flanking sequence and *Adh1*-intron 1 (from the maize alcohol dehydrogenase gene) and sequence from the CaMV 35S promoter. Vectors showing highest expression are fusions of 35S and the *Act1* intron or the *Act1* 5' flanking sequence and the *Act1* intron. The promoter expression cassettes described by McElroy *et al.* (Mol. Gen. Genet. 231: 150-160 (1991)) is easily modified for the expression of a DNA molecule of the present invention and are particularly suitable for use in monocotyledonous hosts. For example, promoter containing fragments are removed from the McElroy constructions and used to replace the double 35S promoter in pCGN1761ENX, which is then available for the insertion of specific gene sequences. The fusion genes thus constructed are transferred to appropriate transformation vectors. In a separate report the rice *Act1*

promoter with its first intron has also been found to direct high expression in cultured barley cells (Chibbar *et al.* Plant Cell Rep. 12: 506-509 (1993)).

A DNA molecule of the present invention is inserted downstream of such promoter, and the fusion products (*i.e.* promoter-gene-terminator) are subsequently transferred to any selected transformation vector, including those described in this application.

#### Constitutive Expression: the Ubiquitin Promoter

Ubiquitin is another gene product known to accumulate in many cell types and its promoter has been cloned from several species for use in transgenic plants (*e.g.* sunflower - Binet *et al.* Plant Science 79: 87-94 (1991), maize - Christensen *et al.* Plant Molec. Biol. 12: 619-632 (1989)). The maize ubiquitin promoter has been developed in transgenic monocot systems and its sequence and vectors constructed for monocot transformation are disclosed in the patent publication EP 0 342 926. Further, Taylor *et al.* (Plant Cell Rep. 12: 491-495 (1993)) describe a vector (pAHC25) which comprises the maize ubiquitin promoter and first intron and its high activity in cell suspensions of numerous monocotyledons when introduced via microprojectile bombardment. The ubiquitin promoter is clearly suitable for the expression of a DNA molecule of the present invention in transgenic plants, especially monocotyledons. Suitable vectors are derivatives of pAHC25 or any of the transformation vectors described in this application, modified by the introduction of the appropriate ubiquitin promoter and/or intron sequences.

A DNA molecule of the present invention is therefore inserted into any of these vector, and the fusion products (*i.e.* promoter-gene-terminator) are used for transformation of plants, resulting in constitutive expression of the DNA molecule.

#### Root Specific Expression

A preferred pattern of expression for a DNA molecule of the instant invention is root expression. Expression of the nucleotide sequence only in root tissue has the advantage of altering the expression of a target gene only in roots, without a concomitant alteration of its expression in leaf and flower tissue and seeds. A suitable root promoter is that described by de Framond (FEBS 290: 103-106 (1991)) and also in the published patent application EP 0 452 269. This promoter is transferred to a suitable vector such as pCGN1761ENX and the DNA molecule is inserted into such vector. The entire promoter-gene-terminator cassette is subsequently transferred to a transformation vector of interest.

### Wound Inducible Promoters

Numerous such promoters have been described (*e.g.* Xu *et al.* Plant Molec. Biol. 22: 573-588 (1993), Logemann *et al.* Plant Cell 1: 151-158 (1989), Rohrmeier & Lehle, Plant Molec. Biol. 22: 783-792 (1993), Firek *et al.* Plant Molec. Biol. 22: 129-142 (1993), Warner *et al.* Plant J. 3: 191-201 (1993)) and all are suitable for use with the instant invention. Logemann *et al.* (*supra*) describe the 5' upstream sequences of the dicotyledonous potato *wun1* gene. Xu *et al.* (*supra*) show that a wound inducible promoter from the dicotyledon potato (*pin2*) is active in the monocotyledon rice. Further, Rohrmeier & Lehle (*supra*) describe the cloning of the maize *Wip1* cDNA which is wound induced and which can be used to isolated the cognate promoter using standard techniques. Similarly, Firek *et al.* (*supra*) and Warner *et al.* (*supra*) have described a wound induced gene from the monocotyledon *Asparagus officinalis* which is expressed at local wound and pathogen invasion sites. Using cloning techniques well known in the art, these promoters can be transferred to suitable vectors, fused to a DNA molecule of this invention, and used to express these genes at the sites of insect pest infection.

### Pith Preferred Expression

Patent application WO 93/07278 describes the isolation of the maize *trpA* gene which is preferentially expressed in pith cells. Using standard molecular biological techniques, this promoter or parts thereof, can be transferred to a vector such as pCGN1761 where it can replace the 35S promoter and be used to drive the expression of a DNA molecule of the present invention in a pith-preferred manner. In fact, fragments containing the pith-preferred promoter or parts thereof are transferred to any vector and modified for utility in transgenic plants. Pith preferred expression of the DNA molecule is achieved by inserting the DNA molecule in such vector.

### Pollen-Specific Expression

Patent Application WO 93/07278 further describes the isolation of the maize calcium-dependent protein kinase (CDPK) gene which is expressed in pollen cells. The gene sequence and promoter extend up to 1400 bp from the start of transcription. Using standard molecular biological techniques, this promoter or parts thereof, is transferred to a vector such as pCGN1761 where it replaces the 35S promoter and is used to drive the expression of a DNA molecule of the present invention in a pollen-specific manner. In fact

fragments containing the pollen-specific promoter or parts thereof can be transferred to any vector and modified for utility in transgenic plants.

#### Leaf-Specific Expression

A maize gene encoding phosphoenol carboxylase (PEPC) has been described by Hudspeth & Grula (Plant Molec Biol 12: 579-589 (1989)). Using standard molecular biological techniques the promoter for this gene is used to drive the expression of a DNA molecule of the present invention in a leaf-specific manner in transgenic plants.

#### **Example 6: Construction of Plant Transformation Vectors**

Numerous transformation vectors are available for plant transformation, and a DNA molecule of this invention is inserted into any of the expression cassettes described above, such that they are capable of expressing the DNA molecule in desirable cells, under appropriate conditions. A nucleotide sequence-containing expression cassette is then incorporated into any appropriate transformation vector described below.

The selection of vector for use will depend upon the preferred transformation technique and the target species for transformation. For certain target species, different antibiotic or herbicide selection markers may be preferred. Selection markers used routinely in transformation include the *nptII* gene which confers resistance to kanamycin and related antibiotics (Messing & Vierra, Gene 19: 259-268 (1982); Bevan *et al.*, Nature 304:184-187 (1983)), the *bar* gene which confers resistance to the herbicide phosphinothricin (White *et al.*, Nucl Acids Res 18: 1062 (1990), Spencer *et al.* Theor Appl Genet 79: 625-631(1990)), the *hph* gene which confers resistance to the antibiotic hygromycin (Blochinger & Diggelmann, Mol Cell Biol 4: 2929-2931), and the *dhfr* gene, which confers resistance to methatrexate (Bourouis *et al.*, EMBO J. 2(7): 1099-1104 (1983)).

#### **Vectors Suitable for *Agrobacterium* Transformation**

Many vectors are available for transformation using *Agrobacterium tumefaciens*. These typically carry at least one T-DNA border sequence and include vectors such as pBIN19 (Bevan, Nucl. Acids Res. (1984)) and pVictor HINK (SEQ ID NO: 5). Below the construction of two typical vectors is described.

#### Construction of pCIB200 and pCIB2001

The binary vectors pCIB200 and pCIB2001 are used for the construction of recombinant vectors for use with *Agrobacterium* and is constructed in the following manner. pTJS75kan is created by *NarI* digestion of pTJS75 (Schmidhauser & Helinski, J Bacteriol. 164: 446-455 (1985)) allowing excision of the tetracycline-resistance gene, followed by insertion of an *AccI* fragment from pUC4K carrying an NPTII (Messing & Vierra, Gene 19: 259-268 (1982); Bevan *et al.*, Nature 304: 184-187 (1983); McBride *et al.*, Plant Molecular Biology 14: 266-276 (1990)). *XhoI* linkers are ligated to the *EcoRV* fragment of pCIB7 which contains the left and right T-DNA borders, a plant selectable *nos/nptII* chimeric gene and the pUC polylinker (Rothstein *et al.*, Gene 53: 153-161 (1987)), and the *XhoI*-digested fragment is cloned into *Sall*-digested pTJS75kan to create pCIB200 (see also EP 0 332 104). pCIB200 contains the following unique polylinker restriction sites: *EcoRI*, *SstI*, *KpnI*, *BglII*, *XbaI*, and *Sall*. pCIB2001 is a derivative of pCIB200 which created by the insertion into the polylinker of additional restriction sites. Unique restriction sites in the polylinker of pCIB2001 are *EcoRI*, *SstI*, *KpnI*, *BglII*, *XbaI*, *Sall*, *MluI*, *BclI*, *AvrII*, *Apal*, *HpaI*, and *StuI*. pCIB2001, in addition to containing these unique restriction sites also has plant and bacterial kanamycin selection, left and right T-DNA borders for *Agrobacterium*-mediated transformation, the RK2-derived *trfA* function for mobilization between *E. coli* and other hosts, and the *OriT* and *OriV* functions also from RK2. The pCIB2001 polylinker is suitable for the cloning of plant expression cassettes containing their own regulatory signals.

Any one of the plant expression cassettes described above and comprising a DNA molecule of the present invention are inserted into pCIB2001, preferably using the polylinker.

#### Construction of pCIB10 and Hygromycin Selection Derivatives thereof

The binary vector pCIB10 contains a gene encoding kanamycin resistance for selection in plants, T-DNA right and left border sequences and incorporates sequences from the wide host-range plasmid pRK252 allowing it to replicate in both *E. coli* and *Agrobacterium*. Its construction is described by Rothstein *et al.* (Gene 53: 153-161 (1987)). Various derivatives of pCIB10 have been constructed which incorporate the gene for hygromycin B phosphotransferase described by Gritz *et al.* (Gene 25: 179-188 (1983)). These derivatives enable selection of transgenic plant cells on hygromycin only (pCIB743), or hygromycin and kanamycin (pCIB715, pCIB717). This vectors is used transform an expression cassette comprising a DNA molecule of the present invention.



**Vectors Suitable for non-*Agrobacterium* Transformation**

Transformation without the use of *Agrobacterium tumefaciens* circumvents the requirement for T-DNA sequences in the chosen transformation vector and consequently vectors lacking these sequences can be utilized in addition to vectors such as the ones described above which contain T-DNA sequences. Transformation techniques which do not rely on *Agrobacterium* include transformation via particle bombardment, protoplast uptake (*e.g.* PEG and electroporation), microinjection or pollen transformation (US Patent 5,629,183). The choice of vector depends largely on the preferred selection for the species being transformed. Below, the construction of some typical vectors is described.

**Construction of pCIB3064**

pCIB3064 is a pUC-derived vector suitable for direct gene transfer techniques in combination with selection by the herbicide basta (or phosphinothricin). The plasmid pCIB246 comprises the CaMV 35S promoter in operational fusion to the *E. coli* GUS gene and the CaMV 35S transcriptional terminator and is described in the PCT published application WO 93/07278. The 35S promoter of this vector contains two ATG sequences 5' of the start site. These sites are mutated using standard PCR techniques in such a way as to remove the ATGs and generate the restriction sites *SspI* and *PvuII*. The new restriction sites are 96 and 37 bp away from the unique *Sall* site and 101 and 42 bp away from the actual start site. The resultant derivative of pCIB246 is designated pCIB3025. The GUS gene is then excised from pCIB3025 by digestion with *Sall* and *SacI*, the termini rendered blunt and religated to generate plasmid pCIB3060. The plasmid pJIT82 is obtained from the John Innes Centre, Norwich and the a 400 bp *SmaI* fragment containing the *bar* gene from *Streptomyces viridochromogenes* is excised and inserted into the *HpaI* site of pCIB3060 (Thompson *et al.* EMBO J 6: 2519-2523 (1987)). This generated pCIB3064 which comprises the *bar* gene under the control of the CaMV 35S promoter and terminator for herbicide selection, a gene for ampicillin resistance (for selection in *E. coli*) and a polylinker with the unique sites *SphI*, *PstI*, *HindIII*, and *BamHI*. This vector is suitable for the cloning of plant expression cassettes containing their own regulatory signals to direct expression of a DNA molecule of the present invention.

### Construction of pSOG19 and pSOG35

pSOG35 is a transformation vector which utilizes the *E. coli* gene dihydrofolate reductase (DHFR) as a selectable marker conferring resistance to methotrexate. PCR is used to amplify the 35S promoter (~800 bp), intron 6 from the maize Adh1 gene (~550 bp) and 18 bp of the GUS untranslated leader sequence from pSOG10. A 250 bp fragment encoding the *E. coli* dihydrofolate reductase type II gene is also amplified by PCR and these two PCR fragments are assembled with a *SacI-PstI* fragment from pBI221 (Clontech) which comprised the pUC19 vector backbone and the nopaline synthase terminator. Assembly of these fragments generated pSOG19 which contains the 35S promoter in fusion with the intron 6 sequence, the GUS leader, the DHFR gene and the nopaline synthase terminator. Replacement of the GUS leader in pSOG19 with the leader sequence from Maize Chlorotic Mottle Virus (MCMV) generated the vector pSOG35. pSOG19 and pSOG35 carry the pUC gene for ampicillin resistance and have *HindIII*, *SphI*, *PstI* and *EcoRI* sites available for the cloning of foreign sequences, in particular a DNA molecule of the present invention.

### **Example 7: Chloroplast Transformation**

#### Transformation vectors

For expression of a DNA molecule of the present invention in plant plastids, plastid transformation vector pPH143 (WO 97/32011, example 36) is used. The DNA molecule is inserted into pPH143 thereby replacing the PROTOX coding sequence. This vector is then used for plastid transformation and selection of transformants for spectinomycin resistance. Alternatively, the DNA molecule is inserted in pPH143 so that it replaces the *aadH* gene. In this case, transformants are selected for resistance to PROTOX inhibitors.

#### Chloroplast Transformation

Seeds of *Nicotiana tabacum* c.v. 'Xanthi nc' were germinated seven per plate in a 1" circular array on T agar medium and bombarded 12-14 days after sowing with 1  $\mu$ m tungsten particles (M10, Biorad, Hercules, CA) coated with DNA from plasmids pPH143 and pPH145 essentially as described (Svab, Z. and Maliga, P. (1993) *PNAS* 90, 913-917). Bombarded seedlings were incubated on T medium for two days after which leaves were excised and placed abaxial side up in bright light (350-500  $\mu$ mol photons/m<sup>2</sup>/s) on plates of RMOP medium (Svab, Z., Hajdukiewicz, P. and Maliga, P. (1990) *PNAS* 87, 8526-8530) containing 500  $\mu$ g/ml spectinomycin dihydrochloride (Sigma, St. Louis, MO). Resistant shoots

appearing underneath the bleached leaves three to eight weeks after bombardment were subcloned onto the same selective medium, allowed to form callus, and secondary shoots isolated and subcloned. Complete segregation of transformed plastid genome copies (homoplasmy) in independent subclones was assessed by standard techniques of Southern blotting (Sambrook et al., (1989) Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor). BamHI/EcoRI-digested total cellular DNA (Mettler, I. J. (1987) *Plant Mol Biol Reporter* 5, 346–349) was separated on 1% Tris-borate (TBE) agarose gels, transferred to nylon membranes (Amersham) and probed with <sup>32</sup>P-labeled random primed DNA sequences corresponding to a 0.7 kb BamHI/HindIII DNA fragment from pC8 containing a portion of the *rps7/12* plastid targeting sequence. Homoplasmic shoots are rooted aseptically on spectinomycin-containing MS/IBA medium (McBride, K. E. et al. (1994) *PNAS* 91, 7301-7305) and transferred to the greenhouse.

**Example 8: Construction of a chimeric gene cassette encoding a sense and antisense (duplex) RNA fragment for the coat protein gene from BWYV, driven by the *Ro/C* promoter**

An 0.6 Kb 'sense' oriented fragment of the beet western yellows virus (BWYV), a so-called virus yellow, coat protein (CP) gene is amplified from plasmid pZU046 using primers HiNK025bis (5' -CAA TTA CCA TGG ACA CGG TCG TGG-3', SEQ ID NO: 6; *NcoI* restriction site underlined), and HiNK226 (5' -GCC AAA TGT TTG AAC GCT GCA GCC TAT TTG-3', SEQ ID NO: 7; *PstI* restriction site underlined). Alternatively the fragment is amplified from plasmid pBW17 (Veidt et al, *Nucleic Acids Research* 16: 9917-9932, 1988; accession number X13063) using primers HiNK025bis2 (5' -AAT CGT CCA TGG ATA CGG TCG TGG-3', SEQ ID NO: 8; nucleotides 3475 to 3498, *NcoI* restriction site underlined), and HiNK226bis (5' -CTA GGG CCG GGT TCC TCT GCA GCC TAT TTG-3', SEQ ID NO: 9; nucleotides 4114 to 4085, *PstI* restriction site underlined). *Taq* DNA Polymerase (Life Technologies) is used in 25µl reactions according to the manufacturer's prescription applying 30 cycles of 94°C/30 sec, 55°C /30 sec, 72°C/90 sec (+2 sec/cycle). The resulting PCR fragment is purified by electrophoresis through a 1% Tris-acetate gel made from Seakem GTG agarose (FMC), followed by an extraction of the gel slices containing the PCR product with QIAquick Gel Extraction Kit (QIAGEN). The PCR product is subsequently digested with *NcoI* and *PstI* (all restriction enzymes were supplied by Life Technologies) according to standard methods and again gel purified. The purified fragment

is ligated between the *RoIC* promoter and the *Nos* terminator using T4 DNA ligase (Life Technologies). The resulting clone is named pHiNK138.

In a similar manner as described above a 1.4 Kb 'antisense' oriented BWYV CP fragment is amplified from plasmid pZU174A using primers HiNK251 (5' -CTC CCA GGT TGA GAC TGC CCT GCA GTG CCC A-3', SEQ ID NO: 10; *PstI* restriction site underlined) and HiNK228 (5' -TTA CCA TGC ATA CGG TCG TGG GTA GG-3', SEQ ID NO: 11; *NsiI* restriction site underlined) or from plasmid pBW17 using primers HiNK251 (nucleotides 4844 to 4814) and HiNK228bis (5' -CGT TAA TGC ATA CGG TCG TGG GTA GG-3', SEQ ID NO: 12; nucleotides 3478 to 3503, *NsiI* restriction site underlined). Upon gel purification the PCR product is digested with *NsiI* and *PstI*. The 4.9 Kb plasmid pHiNK138 is linearised with *PstI* and dephosphorylated using the Thermosensitive Alkaline Phosphatase (Life Technologies). Both the vector and the PCR fragment are gel purified, followed by the bidirectional ligation of the PCR fragment into pHiNK138. The orientation generating the duplex RNA for the CP gene (SEQ ID NO: 13) is identified by restriction site analysis, yielding plasmid pHiNK152 in which the inverted repeat consists of the 0.6 Kb CP gene separated by the 0.7 Kb spacer sequence derived from the BWYV genome downstream of the CP gene, referred to as ORF6. The spacer sequence is in the antisense orientation. Finally, the said gene cassette is transferred to the proprietary binary vector pVictorHiNK carrying phosphomannose isomerase as selectable marker gene (WO 94/20627), yielding pHiNK179.

**Example 9.1: Construction of a chimeric gene cassette encoding a sense and antisense (duplex) RNA fragment for the replicase gene from BNYVV, driven by the *Arabidopsis Ubi3int* promoter**

Total RNA is extracted from sugar beet root infected by the beet necrotic yellow vein virus (BNYVV), a furovirus, using the RNAeasy Plant mini kit from QIAGEN. In order to amplify the 3' end of the BNYVV replicase gene (RNA1) the RNA is reverse transcribed to produce a cDNA using the Superscript<sup>TM</sup> II RNase H-Reverse Transcriptase (RT) (Life Technologies) and the reverse primer HiNK285 (5' -TCG TAG AAG AG A ATT CAC CCA AAC TAT CC-3', SEQ ID NO: 14). Primer HiNK285 is located between nucleotides 6378 and 6405 of the BNYVV RNA1 sequence (accession number D00115) and designed to introduce an *EcoRI* site. The RT reaction is subsequently used as template for two PCR reactions :

- Reaction A using primer HiNK283 (5' -AAG AAT TGC AGG ATC CAC AGG CTC GGT AC-3', SEQ ID NO: 15) located between nucleotides 5168 bp and 5178 bp of BNYVV RNA1 designed to introduce a *Bam*HI site, and primer HiNK284 (5' -TTC CAA CGA ATT CGG TCT CAG AC A-3', SEQ ID NO: 16) located between nucleotides 5597 and 5620 of BNYVV RNA1 designed to introduce an *Eco*RI site.
- Reaction B using primer HiNK283 in combination with primer HiNK285, both described above.

The thus obtained RT-PCR products share the BNYVV RNA1 sequence between nucleotides 5168-5620 that constitutes the future RNA duplex. The future spacer sequence corresponds to nucleotides 5621-6405 bp of BNYVV RNA1 present at the RT-PCR product obtained with primers HiNK283 and HiNK285.

Taq DNA Polymerase (Life Technologies) is used in 25µl reactions according to the suppliers's prescription applying 30 cycles of 94°C/30 sec, 55°C/30 sec, 72°C/90 sec(+2 sec/cycle). The resulting RT-PCR products are purified by electrophoresis through a 1% Tris-acetate gel made from Seakem GTG agarose (FMC), followed by an extraction of the gel slices containing the amplification products with the QIAquick Gel Extraction Kit (QIAGEN). After gel purification, the RT-PCR products are digested with restriction enzymes *Bam*HI and *Eco*RI (Life Technologies) according to standard methods and purified as described above.

Finally the RT-PCR products are cloned between the *Arabidopsis* Ubiquitin3 (*Ubi3int*) promoter and the *Nos* terminator by means of a three-way ligation reaction using T4 DNA ligase (Life Technologies). The two resulting clones are named pHiNK181 (spacer in antisense orientation, see SEQ ID NO: 17) and pHiNK184 (spacer in sense orientation, see SEQ ID NO: 18).

In order to construct the binary vectors for the *Agrobacterium*-mediated transformation of sugar beet, DNA from binary vector pVictorHiNK carrying the phosphomannose isomerase gene as selectable marker (WO 94/20627), as well as plasmids pHiNK181 and pHiNK184, are digested with *Asc*I and *Pac*I (New England Biolabs) and the vector and insert fragments purified by electrophoresis as described above. The resulting 7.7 kb pVictorHiNK vector fragment is ligated using T4 DNA ligase (Life Technologies) to the gene cassettes encoding the duplex RNA for the BNYVV replicase gene yielding pHiNK187 (antisense spacer) and pHiNK188 (sense spacer) respectively.

**Example 9.2: *Agrobacterium*-mediated transformation of sugar beet**

Methods for the *Agrobacterium*-mediated transformation of plants species are well established and known to a person skilled in the art, and may vary for the explant type, the *Agrobacterium* strain, or the selectable marker and regeneration system used. The protocol here below describes the *Agrobacterium*-mediated transformation of sugar beet using cotyledons as source for explants and mannose-6-phosphate isomerase as selectable marker gene (Joersbo et al, Molecular Breeding 4: 111-117, 1998). Upon surface sterilization sugar beet seeds are germinated on water agar and under dim light at a temperature of approximately 12°C. Fully developed cotyledons are removed from the seedling by a transversal cut just below the nodal region and both cotyledons torn apart by gentle pulling and cutting. Cotyledon explants are inoculated by dipping them into a suspension of *Agrobacterium* strain EHA101 carrying the appropriate transformation vector diluted in MS medium pH 5.2, supplemented with 20 g/l sucrose, 0.25 mg/l BA, 0.05 mg/l NAA, 500 µM acetosyringone diluted to an optical density (OD<sub>600</sub>) from 0.1 to 0.3. After five minutes of incubation explants are removed from the *Agrobacterium* suspension, dipped on sterile filter paper to remove excess of the inoculation suspension, and transferred to co-cultivation plates. The co-cultivation plates consist of petri dishes containing 1/10 MS medium pH 5.7, 30 g/l sucrose, 200 µM acetosyringone, solidified with 4.7 g/l agarose and covered with a filter paper moistened with 1.5 ml TXD medium (MS salts supplemented with PGO vitamins, 0.005 mg/l kinetin, 4 mg/l CPA (*p*-chlorophenoxy acetic acid), 30 g/l sucrose, pH 5.7) on the top of the solidified medium. Explants are co-cultivated during 4 days at 21°C and under dim light, and subsequently transferred to selective regeneration medium consisting of MS medium pH 5.9 supplemented with 20 g/l sucrose, 1.25 g/l mannose, 0.25 mg/l BA, 0.05 mg/l NAA, 500 mg/l carbenicillin, and solidified with 9 g/l agar. Every third week the explants are subcultured to fresh media containing gradually increasing concentrations of mannose to a maximum of 15 g/l. After 12 weeks of selection and regeneration at a temperature of 21°C, regenerated shoots are harvested, rooted and analyzed for PMI activity essentially according to the coupled enzyme assay described by Feramisco and co-workers (Feramisco et al, Biochem. Biophys. Res. Comm. 55: 636-641, 1973). Positive plants are potted in soil and finally transferred to the greenhouse.

**Example 9.3: Screening for resistance to rhizomania**

Upon sowing or potting to soil, seedlings or T0 transformants are first allowed to establish a sufficiently developed root system for a period of approximately four weeks, prior to their transfer to soil infested with *Polymyxa betae* carrying BNYVV. Infested soils are collected from rhizomania infected fields in Germany. During the resistance assay plants are grown in 12 cm pots at a temperature of approximately 21°C and light period of 16 hours. Four weeks after transplantation into the infested soil, plants are pulled from the soil and the bottom half of the root system cleaned from any adhering dirt by rinsing with water. Sap from a random sample of 0.5 g of root tissue is collected by means of a Pollähne press and added to 10 ml of extraction buffer consisting of phosphate buffered saline pH 7.2, supplemented with 2% PVP and 0.2% ovalbumin. The amount of virus present in the samples (clones are obtained by *in vitro* propagation) is determined by means of the triple antibody sandwich (TAS) ELISA for BNYVV commercialized by Adgen Ltd, Scotland, UK, essentially following the supplier's instruction. A standard curve is included on each plate to calculate the virus content of the root samples from the measured absorbance values. Non-transformed susceptible sugar beet plants serve as negative controls, plants carrying the C28 gene for natural rhizomania resistance as positive controls. Table 1 summarizes the results of transformation events obtained with plasmid pHINK188.

**Table 1:**

Event	Clone number	ELISA value	Virus content ng/ml
Event 279-15-A	1	3.265	>900
	2	3.420	>900
	3	2.987	>900
Event 284-22-A	1	0.119	4
Event 284-22-G	1	0.022	0
	2	0.006	0
Event 284-22-I	1	0.010	0
Event 284-22-M	1	1.400	216
	2	1.127	138
Event 284-22-Q	1	0.447	29
	2	0.049	1
Event 284-22-U	1	3.420	>900
	2	3.582	>900

Event	Clone number	ELISA value	Virus content ng/ml
Event 284-22-1F	1	3.945	>900
	2	0.131	4
C28 positive control	1	0.677	56
	2	0.679	56
	3	0.377	22
	4	0.756	67
	5	1.122	137
	6	0.640	51
Negative control A	1	3.186	>900
	2	3.362	>900
	3	3.487	>900
	4	3.311	>900
	5	3.478	>900
Negative control B	1	3.678	>900
	2	3.582	>900
	3	3.326	>900
	4	3.502	>900
	5	3.330	>900
	6	3.439	>900
	7	3.439	>900
	8	3.682	>900

**Example 10: Construction of a plant transformation vector for Zucchini yellow mosaic potyvirus (ZYMV) and Papaya ringspot potyvirus (PRSV) resistance in Melon:**

The NOS terminator (Bevan, M., et al, 1983 *Nucleic Acids Res.* 11 (2), 369-385) is cloned as 260 bp HindIII/PstI fragment into the plasmid pZO1560 digested with HindIII/PstI.

PZO1560 is a pUC derived plasmid in which the multiple cloning site has been replaced by a more versatile one. The new construct obtained after insertion of the NOS terminator is named pZU533.

The 1728 bp Ubi3 promoter/intron fragment (Callis, J., et al, (1995 *Genetics* 139 (2), 921-939) is isolated by digestion with BamHI followed by a T4 DNA polymerase treatment and KpnI digestion. This fragment is cloned into pZU533 digested with SmaI. The new construct is named pZU615.



Additional DNA fragments to be inserted into pZU615 are firstly amplified by PCR using Pfx DNA polymerase and the PCR fragments obtained are cloned into pBluescript SK+.

To amplify a 513 bp Actin2 IntronL (leader intron) fragment two primers are designed based on the sequence from An et al, *The Plant Journal*: 10: 107-121, 1996. The 5' primer

(ZUP1563: 5' -GGGCGGATCCGCTAGCCCCGCGCGCTCTTTCTTTCCAAGG-3', SEQ ID NO:

19) anneals directly upstream of the 5' splice site and adds a BamHI, a NheI and a SacII

restriction site to the 5'-end of the Actin2 IntronL fragment to be amplified. The 3' primer

(ZUP1564: 5' -CCCGCCATGGGTCGACGCCATTTTTTATGAGCTGC-3', SEQ ID NO: 20)

anneals directly downstream of the 3' splice site and adds a Sall and a NcoI restriction site

to the 3'-end of the Actin2 IntronL fragment to be amplified. The PCR fragment amplified

with ZUP1563 and 1564 is cloned in the EcoRV site of pBluescript. The new plasmid is

named pZU611. To provide plasmid pZU615 with the Act2 IntronL a 499 bp BamH/NcoI

Act2 IntronL fragment is isolated from pZU611 and cloned in pZU615 digested with BamHI

and NcoI downstream of the Ubi3 promoter/intron and upstream of the NOS terminator. The

new construct is designated pZU616. The insertion of this fragment simultaneously provides

the cassette with five additional restriction sites for the next three cloning steps.

To amplify a non-translated (nt) 739 bp PRSV CP fragment (Shyi-Dong, Y., et al, (1992).

*Journal of General Virology* 73, 2531-2541) two primers are designed based on the

sequence of a French field isolate from Shyi-Dong Yeh. The 5' primer (ZUP1565: 5' -

CCCGCCATGGGATCCGATGATTTCTACCGAGAATTAAGGG -3', SEQ ID NO: 21) anneals 285

bp downstream of the start codon of PRSV CP and adds a NcoI and a BamHI restriction site

to the 5'-end of the non-translated PRSV CP fragment. The 3' primer (ZUP1566: 5' -

GGGCGCTAGCCTAATGCTTATATAGTACC-3', SEQ ID NO: 22) anneals 55 bp downstream of

the PRSV CP stop codon and adds a NheI restriction site to the 3'-end of the non-translated

PRSV CP fragment. The amplified PCR fragment is cloned in the EcoRV site of pBluescript

and the new plasmid is designated pZU612.

To amplify a 735 bp non-translated ZYMV CP fragment (Gal-On, A., et al, (1990). *Gene* 87,

273-277) two primers are designed based on the sequence of a French field isolate from

Gal-On, A.. The 5' primer (ZUP1567: 5' - GGGCGCTAGCCTTGCTGGAGTATAAGCCGG -3',

SEQ ID NO: 23) anneals 253 bp downstream of the start codon of ZYMV CP and includes a

NheI restriction site at the 5'-end of the ZYMV CP non-translated fragment. The 3' primer

(ZUP1568: 5' - GGGCGTCGACCGCGGGCTTTAAAGGTGGGAGGCCC -3', SEQ ID NO: 24)

anneals 89 bp downstream of the ZYMV CP stop codon and includes SacII and a Sall

restriction sites at the 3' end of the non-translated ZYMV CP fragment. The amplified PCR fragment is cloned in the EcoRV site of pBluescript. The new plasmid is named pZU613. A ZYMV CP non-translated fragment is subsequently cloned into pZU616 downstream of the Ubi3 promoter/intron and upstream of the Act2 IntronL. For this purpose a 719 bp NheI/SacII ZYMV CP non-translated fragment is isolated from pZU613 and cloned in the NheI and SacII sites of pZU616. The construct is designated pZU617. Subsequently a PRSV CP non-translated fragment is cloned into pZU617 downstream of the Ubi3 promoter/intron and upstream of the ZYMV CP non-translated fragment. For this purpose a 720 bp BamHI/NheI PRSV CP non-translated fragment is isolated from pZU612 and cloned in the BamHI and NheI sites of pZU617. This new construct is named pZU618.

The last fragment to be cloned to complete the gene cassette contains a PRSV CP non-translated fragment and downstream thereof a ZYMV CP non-translated fragment in the same orientation. A corresponding fragment is amplified from pZU618 as template using Pfx PCR and the primers ZUP1565 and ZUP1568. The PCR fragment is cloned into the EcoRV site of pBluescript SK+ and the resulting plasmid is named pZU619.

To create an inverted repeat gene cassette the PRSV CP (nt) / ZYMV CP (nt) fragment is inserted in pZU618 in opposite direction of the PRSV CP (nt) / ZYMV CP (nt) fragments already present in the pZU618 plasmid. For this purpose a 1445 bp Sall/NcoI PRSV CP (nt) / ZYMV CP (nt) fragment is isolated from pZU619 and cloned in pZU618 digested with Sall and NcoI downstream of the Act2 IntronL and upstream of the NOS terminator. The resulting plasmid is designated pZU622. Said cassette is inserted into the binary vector pZU547, a binary vector derived from the plasmid pVictorHink additionally containing a SMAS promoter / PMI / NOS terminator selection cassette. To this end the 5414 bp AscI/PacI DNA fragment containing the inverted repeat gene cassette is isolated from pZU622 and cloned into the AscI and PacI sites of pZU547 in tandem orientation and upstream of the selection cassette. The final construct is designated pZU623 (SEQ ID NO: 25).

#### **Example 11: Construction of a plant transformation vector for Potato Virus Y (PVY) resistance in Tomato**

Based on the sequence of PVYn (a French field isolate of PVY), published in the thesis 'Engineering resistance against potato virus Y' of R.A.A. van der Vlugt (1993), two primers (ZUP1598: 5' -CATGCCATGGATCCAATGGCCACGAATTAAAGCTATCACGTC-3' - SEQ ID NO: 26, and ZUP1590: 5' -ACGCGTCGACCGCGGATTCAAACGATTATTAATTACGATAAAAG-3' -

SEQ ID NO: 27) are used to amplify by standard PCR techniques using Platinum Pfx DNA polymerase from Life Technologies a 804 bp fragment containing the coat protein cistron sequences and 99 nucleotides of the 3'-end non-translated region. The amplified PCR fragment is cloned as a blunt end fragment in the EcoRV site of pBluescript SK+ the plasmid being designated pZUA. The amplified PVY specific insert is excised from as a BamHI/SacII fragment and cloned into the BamHI/SacII sites of pZU616 (see example 10), yielding pZUB. pZUB and pZUA are both digested with NcoI and Sall. The PVY specific fragment from pZUA is purified from agarose gel and ligated into the pZUB digested with NcoI and Sall, yielding pZUC containing the following elements:

The UBI3 promoter with intron followed by the PVY PCR product in sense orientation as a BamHI/SacII fragment, followed by a SacII/Sall ACT2 intron, followed by the PVY PCR product in antisense orientation as a Sall/NcoI fragment and finally a nos terminator as a NcoI/HindIII fragment. Finally, pZUC is cloned into the binary vector pZU547 containing the SMAS promoter / PMI / NOS terminator selection cassette derived from the pHINK 085 binary vector. The final construct is designated pZU634 (SEQ ID NO: 28).

#### **Example 12: Transformation of binary vectors to melon and tomato plant material**

Methods to transfer binary vectors to plant material are well established and known to a person skilled in the art. Variations in the procedures are due to, for instance, differences in *Agrobacterium* strains used, different sources of explant material, differences between the regeneration systems, as well as different cultivars of the plant species to be transformed. The binary plant transformation vectors described in examples 10 and 11 above are used in transformation experiments according to the following procedures. The binary vectors are transferred to *Agrobacterium tumefaciens* by electroporation, followed by inoculation and cocultivation of plant explant material with the transformed *Agrobacterium* strain, selective killing of the *Agrobacterium* strain using an appropriate antibiotic, selection of transformed cells by growing on selective media containing mannose, transfer of tissue to shoot inducing media, transfer of selected shoots to root inducing media, and transfer of plantlets to soil. To confirm the presence of the gene cassettes described in examples 10 and 11 above, total DNA from the transgenic plants is characterized using well known Southern Blot Analysis techniques.

**Example 13: Screening transgenic melon plants for ZYMV and PRSV resistance**

Transformed plants are grown in the greenhouse under standard quarantine conditions in order to prevent any infections by pathogens. Primary transformants are self pollinated and seeds harvested.

100 plants of the S1 progeny of the primary transformants are analyzed for segregation of the inserted gene and subsequently infected with ZYMV by mechanical inoculation. Tissue from host plants systemically infected with ZYMV is ground in 5 volumes of ice cold inoculation buffer (10mM phosphate buffer) and rubbed in the presence of carborundum powder on the cotyledons and first leave of 1 week old seedlings. Inoculated plants are monitored for symptom development during 3 weeks after inoculation. Plants containing ZYMV sequences show reduced susceptibility to ZYMV infection compared with untransformed control plants which show severe systemic ZYMV symptoms within 7 days after inoculation. ZYMV tolerant plants are self pollinated and seeds harvested. Transgenic ZYMV resistant plants are mechanically inoculated with PRSV according to the procedures described above. Plants already resistant to ZYMV also show reduced susceptibility to PRSV infection compared with untransformed control plants which show severe systemic PRSV symptoms within 7 days after inoculation.

**Example 14: Screening of transgenic tomato plants for resistance against PVY**

Transformed plants are grown in the greenhouse under standard quarantine conditions in order to prevent any infections by pathogens. Primary transformants are self pollinated and seeds harvested.

50 plants of the S1 progeny of the primary transformants are analyzed for segregation of the inserted gene and subsequently infected with PVY by mechanical inoculation. Tissue from host plants systemically infected with PVY is ground in 5 volumes of ice cold inoculation buffer (10mM phosphate buffer) and rubbed in the presence of carborundum powder on the first two fully extended leaves of 5 weeks old seedlings. Inoculated plants are monitored for symptom development during 3 weeks after inoculation. Plants containing PVY sequences show reduced susceptibility to PVY infection compared with untransformed control plants which show severe systemic PVY symptoms within 7 days after inoculation.

The above disclosed embodiments are illustrative. This disclosure of the invention will place one skilled in the art in possession of many variations of the invention. All such obvious and foreseeable variations are intended to be encompassed by the appended claims.

***What is claimed is:***

1. A method of altering the expression of a viral genome comprising introducing into a cell a first DNA sequence capable of expressing in said cell a sense RNA fragment of said viral genome and a second DNA sequence capable of expressing in said cell an antisense RNA fragment of said viral genome, wherein said sense RNA fragment and said antisense RNA fragment are capable of forming double-stranded RNA.
2. The method of claim 1 rendering said cell virus resistant or tolerant.
3. The method of claim 1, wherein said cell is a plant cell.
4. The method of claim 1, wherein said virus is selected from the group consisting of tospoviruses, potyviruses, potexviruses, tobamoviruses, luteoviruses, cucumoviruses, bromoviruses, closteorviruses, tombusviruses and furoviruses.
5. The method of claim 1, wherein said DNA sequences comprises a nucleotide sequence derived from a viral coat protein gene, a viral nucleocapsid protein gene, a viral replicase gene, or a viral movement protein gene.
6. The method of claim 1, wherein said first DNA sequence and said second DNA sequence are stably integrated in the genome of said cell.
7. The method of claim 1, wherein said first DNA sequence and said second DNA sequence are comprised in two separate DNA molecules.
8. The method of claim 1, wherein at least two pairs of first and second DNA sequences are introduced into a cell.
9. The method of claim 8, wherein each pair of DNA sequences encodes sense and antisense RNA fragments of different virus species or isolates.
10. The method of claim 1, wherein said first DNA sequence and said second DNA sequence are comprised in one DNA molecule.
11. The method of claim 10, wherein said first DNA sequence and said second DNA sequence are comprised in the same DNA strand of said DNA molecule.
12. The method of claim 11, wherein said sense RNA fragment and said antisense RNA fragment are comprised in one RNA molecule.

13. The method of claim 12, wherein said RNA molecule is capable of folding such that said RNA fragments comprised therein form a double-stranded region.
14. The method of claim 1, wherein the the expressed RNA molecule comprises the inverted repeat sequence of SEQ ID NO: 13, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 25 or SEQ ID NO: 28.
15. The method of claim 24, wherein expression of said RNA molecule is driven by a heterologous, a tissue-specific, a developmentally regulated, a constitutive, or an inducible promoter.
16. The method of claim 15, wherein expression of said RNA molecule is driven by a ubiquitin promoter such as the Arabidopsis Ubi3 promoter.
17. The method of claim 15, wherein expression of said RNA molecule is driven by the Agrobacterium rolC promoter.
18. The method of claim 12, wherein said DNA molecule comprises a linker between the DNA sequences encoding said sense RNA fragment and said antisense RNA fragments.
19. The method of claim 18, wherein the linker is defined by the nucleotide sequence of the leader intron of the Arabidopsis Actin 2 gene.
20. The method of claim 18, wherein the linker is defined by a nucleotide sequence of the viral region flanking the sense or antisense RNA fragment.
21. The method of claim 18, wherein said linker comprises an expression cassette of a functional gene such as a selectable marker gene.
22. The method of claim 21, wherein said linker comprises regulatory sequences such as intron processing signals.
23. The method of claim 11, wherein said sense RNA fragment and said antisense RNA fragment are comprised in two separate RNA molecules.
24. The method of claim 23, wherein said first DNA sequence and said second DNA sequence are operably linked to a bi-directional promoter.
25. The method of claim 11, wherein said first DNA sequence and said second DNA sequence are comprised in complementary strands of said DNA molecule.

26. The method of claim 25, wherein said first DNA sequence is the complementary DNA strand of said second DNA sequence in said DNA molecule.
27. A DNA construct altering the expression of a viral genome comprising a first DNA sequence capable of expressing in a cell a sense RNA fragment of said viral genome and a second DNA sequence capable of expressing in said cell an antisense RNA fragment of said viral genome, wherein said sense RNA fragment and said antisense RNA fragment are capable of forming a double-stranded RNA molecule.
28. The DNA construct of claim 27, wherein said DNA construct comprises a first promoter operably linked to said first DNA sequence and a second promoter operably linked to said second DNA sequence.
29. The DNA construct of claim 27, wherein said DNA construct comprises a bi-directional promoter operably linked to said first DNA sequence and to said second DNA sequence.
30. A cell showing altered expression of a viral genome comprising a first DNA sequence capable of expressing in said cell a sense RNA fragment of said viral genome and a second DNA sequence capable of expressing in said cell an antisense RNA fragment of said viral genome, wherein said sense RNA fragment and said antisense RNA fragment are capable of forming double-stranded RNA.
31. A plant and the progeny thereof derived showing altered expression of a viral genome comprising a first DNA sequence capable of expressing in said cell a sense RNA fragment of said viral genome and a second DNA sequence capable of expressing in said cell an antisense RNA fragment of said viral genome, wherein said sense RNA fragment and said antisense RNA fragment are capable of forming double-stranded RNA.
32. The plant of claim 31, wherein said plant is virus resistant or tolerant.
33. Seeds derived from the plant of claim 31.



## SEQUENCE LISTING

<110> Novartis AG

<120> Regulation of Viral Gene Expression

<130> S-30959A

<140>

<141>

<150> US 09/309038

<151> 1999-05-10

<160> 28

<170> PatentIn Ver. 2.1

<210> 1

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: ds\_Luc1

<400> 1

cgcggtatcct ggaagacgcc aaaaaca

27

<210> 2

<211> 38

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: ds\_Luc2

<400> 2

cggaagctta ggctgccta atcgagtat ccggaatg

38

<210> 3

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: ds\_Luc3

<400> 3

cgtctagag gaagaccca aaaacata

28

<210> 4

<211> 22

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: JG-L

&lt;400&gt; 4

gtacctcgag tctagactcg ag

22

&lt;210&gt; 5

&lt;211&gt; 4732

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: pVictorHINK

&lt;400&gt; 5

```

gcacgaaccc cccgttcagc cgcacgcgtg cgccttatcc ggtaactatc gtcttgagtc 60
caaccgcgta agacacgact tatcgccact ggcagcagcc actggtaaca ggattagcag 120
agcgaggatg tagggcggtg ctacagagtt cttgaagtgg tggcctaact acggctacac 180
tagaaggaca gtatttggtg tctgcgtctt gctgaagcca gttaccttcg gaaaaagagt 240
tggtagctct tgatcccgca aacaaaccac cgctggtagc ggtgggtttt ttgtttgcaa 300
gcagcagatt acgcgcagaa aaaaaggatc tcaagaagat cctttgatct tttctacggg 360
gtctgacgct cagtggaaacg aaaactcacg ttaagggatt ttggtcatga gattatcaaa 420
aaggatcttc acctagatcc ttttgatccg gaattaattc ctgtgggttg catgcacata 480
caaatggagc aacggataaa ccttttcacg cccttttaaa tatccgatta ttctaataaa 540
cgctcttttc tcttaggttt acccgccaat atatcctgtc aaacactgat agtttaaact 600
gaaggcggtg aacgacaatc tgatcatgag cggagaatta agggagtcac gttatgacct 660
ccgccgatga cgcgggacaa gccgttttac gtttggaact gacagaaccg caacgctgca 720
ggaattggcc gcagcggcca tttaaatcaa ttgggcgcgc cgaattcgag ctcggtacct 780
ggggatcctc tagagtcgac catggtgatc actgcaggca tgcaagcttc gtacgttaat 840
taattcgaat cgggagcggc cgcacgcgtg gggccgttta aacctcgaga gatctgctag 900
ccctgcagga aatttaccgg tgcccgggcg gccagcatgg ccgtatccgc aatgtgttat 960
taagtgtgtc aagcgtcaat ttgtttacac cacaatatat cctgccacca gccagccaac 1020
agctcccccga cggcgagctc ggcacaaaat caccactcga tacaggcagc ccatcagaat 1080
taattctcat gtttgacagc ttatcatcga ctgcacgggt caccaatgct tctggcgta 1140
ggcagccatc ggaagctgtg gtatggctgt gcaggctcga aatcactgca taattcgtgt 1200
cgctcaaggc gcaactccgt tctggataat gttttttcgc ccgacatcat aacggttctg 1260
gcaaatattc tgaaatgagc tgttgacaat taatcatcgg ctcgataat gtgtggaatt 1320
gtgagcggat aacaatttca cacaggaaac agaccatgag ggaagcgggt atcgccgaag 1380
tatcgactca actatcagag gtatgtggcg tcatcgagcg ccatctcgaa cgcggttg 1440
tggccgtaca tttgtacggc tccgcagtg atggcggcct gaagccacac agtgatattg 1500
atttgcgtgt tacggtgacc gtaaggcttg atgaaacaac gcggcgagct ttgatcaacg 1560
accttttggg aacttcggct tcccctggag agagcgagat tctccgcgt gtagaagtca 1620
ccattgttgt gcacgacgac atcattccgt ggcgttatcc agctaagcgc gaactgcaat 1680
ttggagaatg gcagcgcaat gacattcttg caggatctct cgagccagcc acgatcgaca 1740
ttgatctggc tatcttgctg acaaaagcaa gagaacatag cgttgccctg gtaggtccag 1800
cggcggagga actctttgat cgggttctct aacaggatct atttgaggcg ctaaatgaaa 1860
ccttaacgct atggaactcg ccgcccagc gggctggcga tgagcgaaat gtatgtctta 1920
cgttgtcccg cattttggtac agcgcagtaa ccggcaaaat cgcgccgaag gatgtcgtg 1980
ccgactgggc aatggagcgc ctgcccggcc agtatcagcc cgtcatactt gaagctagtc 2040
aggcttatct tggacaagaa gatcgcttgg cctcgcgcgc agatcagttg gaagaatttg 2100
ttcactacgt gaaaggcgag atcaccaagg tagtcggcaa ataaagctct agtggatccc 2160
cgaggaatcg gcgtgacggt cgcaaaccat ccggcccggt acaaatcggc gcggcgctgy 2220

```

```

gtgatgacct ggtggagaag ttgaaggcgg cgcaggccgc ccagcggcaa cgcacgcagg 2280
cagaagcacg ccccggtgaa tcgtggcaag cggccgctga tcgaatccgc aaagaatccc 2340
ggcaaccgcc ggcagccggt gcgcgctoga ttaggaagcc gcccaagggc gacgagcaac 2400
cagatttttt cgttccgatg ctctatgacg tgggcacccg cgatagtcgc agcatcatgg 2460
acgtggcggc tttcgtctg tcgaagcgtg accgacgagc tggcgagggtg atccgctacg 2520
agcttccaga cgggcacgta gaggtttcag cagggccggc cggcatggcc agtgtgtggg 2580
attaagacct ggtactgatg gcggtttccc atctaaccga atccatgaac cgataccggg 2640
aagggaaggg agacaagccc ggcgcgctgt tccgtccaca cgttgcggac gtactcaagt 2700
tctgcccggc agccgatggc ggaaagcaga aagacgacct ggtagaaacc tgcattcggg 2760
taaacaccac gcacgttgcc atgcagcgtg cgaagaaggc caagaacggc cgcctggtga 2820
cggtatccga ggggtgaagc ttgattagcc gctacaagat cgtaaagagc gaaaccgggc 2880
ggccggagta catcgagatc gagctagctg attggatgta ccgcgagatc acagaaggca 2940
agaaccggga cgtgctgacg gttcaccccg attacttttt gatcgatccc ggcatcggcc 3000
gttttctcta ccgcctggca cgcgcgcggc caggcaaggc agaagccaga tggttgttca 3060
agacgatcta cgaacgcagt ggcagcgcgg gagagttcaa gaagtctgt ttcaccgtgc 3120
gcaagctgat cgggtcaaat gacctgccgg agtacgattt gaaggaggag gcggggcagg 3180
ctggcccgat cctagtcagc cgtaccgca acctgatoga gggcgaaagc tccgcgggtt 3240
cctaattgtac ggagcagatg ctagggcaaa ttgccctagc aggggaaaaa ggtcgaaaaa 3300
gtctctttcc tgtggatagc acgtacattg ggaacccaaa gccgtacatt gggaaaccga 3360
accgctacat tgggaaccca aagccgtaca ttgggaaccg gtcacacatg taagtgactg 3420
atataaaaga gaaaaaaggc gatttttccg cctaaaactc tttaaaactt attaaaactc 3480
ttaaaacccg cctggcctgt gcataactgt ctggccagcg cacagccgaa gagctgcaaa 3540
aagcgctac ccttcggtcg ctgcgctccc tacgcccgc cgcttcgctg cggcctatcg 3600
cggccgctgg ccgctcaaaa atggctggcc tacggccagg caatctacca gggcgcgac 3660
aagccgcgcc gtcgccactc gaccgcggc gctgaggtct gcctcgtgaa gaaggtgttg 3720
ctgactcata ccaggcctga atcgcccat catccagcca gaaagtgagg gagccacggg 3780
tgatgagagc tttgtgttag gtggaccagt tggtgatttt gaacttttgc tttgccacgg 3840
aacggtctgc gttgtcggga agatgcgtga tctgacctt caactcagca aaagtccgat 3900
ttattcaaca aagccgcgt cccgtcaagt cagcgtaatg ctctgccagt gttacaacca 3960
attaaccaat tctgattaga aaaactcatc gagcatcaaa tgaaactgca atttattcat 4020
atcaggatta tcaataccat atttttgaaa aagccgtttc tgtaatgaag gagaaaactc 4080
accgaggcag ttccatagga tggcaagatc ctggtatcgg tctgcgattc cgactcgtcc 4140
aacatcaata caacctatta atttcccctc gtcaaaaata aggttatcaa gtgagaaatc 4200
accatgagtg acgactgaat ccggtgagaa tggcaaaagc tctgcattaa tgaatcggcc 4260
aacgcgcggg gagaggcggg ttgcgtattg ggcgctcttc cgcttcctcg ctcactgact 4320
cgctgcgctc ggtcgttcgg ctgcggcgag cggtatcagc tcaactcaaag gcggtataac 4380
ggttatccac agaactcagg gataacgcag gaaagaacat gtgagcaaaa ggccagcaaa 4440
aggccaggaa ccgtaaaaag gccgcgttgc tggcggtttt ccataggctc cgccccctg 4500
acgagcatca caaaaatcga cgctcaagtc agaggtggcg aaacccgaca ggactataaa 4560
gataccaggc gtttccccct ggaagctccc tcgtgcgctc tcctgttccg accctgccgc 4620
ttaccggata cctgtccgcc tttctccctt cgggaagcgt ggcgctttct caatgctcac 4680
gctgtaggta tctcagttcg gtgtaggtcg ttcgctccaa gctgggctgt gt 4732

```

&lt;210&gt; 6

&lt;211&gt; 24

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: HiNK025bis

&lt;400&gt; 6

caattaccat ggacacgggc gtgg

24

<210> 7  
<211> 30  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: HiNK226

<400> 7  
gccaaatggt tgaacgctgc agcctatttg

30

<210> 8  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: HiNK025bis2

<400> 8  
aatcgccat ggatacggc gtgg

24

<210> 9  
<211> 30  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: HiNK226bis

<400> 9  
ctagggccgg gttcctctgc agcctatttg

30

<210> 10  
<211> 31  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: HiNK251

<400> 10  
ctcccaggtt gagactgcc tgcagtgcc a

31

<210> 11  
<211> 26  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: HiNK228

&lt;400&gt; 11

ttaccatgca tacggtcgtg ggtagg

26

&lt;210&gt; 12

&lt;211&gt; 26

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: HiNK228bis

&lt;400&gt; 12

cgттаатgca tacggtcgtg ggtagg

26

&lt;210&gt; 13

&lt;211&gt; 3338

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: BWYV duplex  
RNA gene

&lt;220&gt;

&lt;221&gt; promoter

&lt;222&gt; (1)..(1131)

&lt;223&gt; RolC promoter

&lt;220&gt;

&lt;221&gt; repeat\_unit

&lt;222&gt; (1132)..(1737)

&lt;223&gt; BWYV CP inverted repeat fragment

&lt;220&gt;

&lt;221&gt; stem\_loop

&lt;222&gt; (1738)..(2470)

&lt;223&gt; 0.7 Kb spacer fragment downstream of BWYV CP gene

&lt;220&gt;

&lt;221&gt; repeat\_unit

&lt;222&gt; (2471)..(3074)

&lt;223&gt; BWYV CP inverted repeat fragment

&lt;220&gt;

&lt;221&gt; terminator

&lt;222&gt; (3076)..(3338)

&lt;223&gt; NOS terminator

&lt;400&gt; 13

ggatccggcg tcggaaactg gcgccaatca gacacagtct ctggtcggga aagccagagg 60  
tagtttgga acaatcacat caagatcgat gcgcaagaca cgggaggcct taaaatctgg 120  
atcaagcgaa aatactgcat gcgtgatcgt tcatgggttc atagtactgg gtttgctttt 180  
tcttgctgtg ttgtttggcc ttagcgaaag gatgtcaaaa aaggatgccc ataattggga 240  
ggagtggggg aaagcttaaa gttggccgc tattggattt cgcgaaagcg cattggcaaa 300

```

cgtgaagatt gctgcattca agatactttt tctattttct ggttaagatg taaagtattg 360
ccacaatcat attaatctact aacattgtat atgtaatatata gtgcggaaat tatctatgcc 420
aaaatgatgt attaataata gcaataataa tatgtgttaa tctttttcaa tcgggaatac 480
gtttaagcga ttatcgtgtt gaataaatta ttccaaaagg aaatacatgg ttttggagaa 540
cctgctatag atatatgcc aatttact agtttagtgg gtgcaaaact attatctctg 600
tttctgagtt taataaaaaa taaataagca gggcgaatag cagttagcct aagaaggaat 660
ggtggccatg tacgtgcttt taagagaccc tataataaat tgccagctgt gttgctttgg 720
tgccgacagg cctaacgtgg ggttttagctt gacaaagtag cgcctttccg cagcataaat 780
aaaggtaggc ggtgctgctc cattattaaa ggaaaaagca aaagctgaga ttccatagac 840
cacaaccac cattattgga ggacagaacc tattccctca cgtgggtcgc tgagctttaa 900
acctaataag taaaaacaat taaaagcagg caggtgtccc ttctatattc gcacaacgag 960
gcgacgtgga gcatcgacag ccgcatccat taattaataa atttgtggac ctatacctaa 1020
ctcaaataatt ttattatttt gctccaatac gctaagagct ctggattata aatagtttgg 1080
atgcttcgag ttatgggtac aagcaacctg tttcctactt tgttaccatg gacacggtcg 1140
tgggtaggag aattatcaat ggaagaagac gaccacgcag gcaaacacga cgcgctcagc 1200
gccctcagcc agtggttgtg gtccaaacct ctcgggcaac acaacgccga cctagacgac 1260
gacgaagagg taacaaccgg acaggaagaa ctgttcctac cagaggagca ggttcgagcg 1320
agacatttgt tttctcaaaa gacaatctcg cgggaagtcc cagcggagca atcagttcg 1380
ggcgcagctc atcagactgc ccggcattct ctaatggaat gctcaaggcc taccatgagt 1440
ataaaatctc atagggtcatt ttggagtctg tctccgaagc ctcttcccaa aattccggtt 1500
ccatcgctta cgagctggac ccacactgta aactcaactc cctttcctca actatcaaca 1560
agttcgggat cacaagccc gggaaaaggg cgtttacagc gtcttacatc aacggaacgg 1620
aatggcacga cgttgccgag gaccaattca ggatcctcta caaaggcaat ggttcttcat 1680
cgatagctgg ttctttcaga atcaccatta agtgtcaatt ccacaacccc aaataggctg 1740
cagtgcctaa ctctctttgg tctttctgtc ttacggaaac cggatgagcc ttgttcatca 1800
agtgtatagg cgatcatccc tatctccatc atccgatctg tccaggctcc gtacgaaacg 1860
gcgttaattat atttagattg cttctggaca gcgggtccaa caacaaagaa ggaggcattg 1920
tcaccagtgc tcttgatag acaagtcaaa tctccatctc tttccagaca ctgtccttga 1980
ttgaaatgac agccattgag ttccatgtct ggttggccat acttcaaagt attatcggcc 2040
ttgttgttgg ttatctccac attattgtaa atccccacgt tccaaccttc actaatgata 2100
tcgttgtagg cgatgagacc atcttgtttg tcttgttag gatctgtggt gcttgagggt 2160
ggttgatacc cctccatcga tttttccacg gtccactcac cttgaggggac tggcactatt 2220
atcatcgga tggctttcaa agaattctgg gaataaccatc gagaatcgag gttcgtccag 2280
ttcatgttct cgtcctctat gtagcgaac cgttgggacg gcatatcata caaagagatg 2340
gcatcatccg tagattgagc cattatacga gtcacgggga ctccagtata gacgataaaa 2400
cgataattct tttgggtgt ggttgtgga gagggagaag gccctgggct agggccgggt 2460
tctcgtctca cctatttggg gttgtggaat tgacacttaa tgggtgattct gaaagaacca 2520
gctatcgatg aagaaccatt gcctttgtag aggatcctga attggtcctc ggcaacgtcg 2580
tgccattccg ttccgttgat gtaagacgct gtaaacgccc ttttccggg ctttgtgatc 2640
ccgaacttgt tgatagttga ggaaaggag ttgagtttac agtgtgtggtc cagctcgtaa 2700
gcgatggaac cggaattttg ggaagaggct tcggagacga actccaaaat gaccattgag 2760
attttatact catggtaggc cttgagcatt ccattagaga atgccgggca gtctgataga 2820
ctcggcccca acgtgattgc tccgctggaa cttcccgga gattgtcttt tgagaaaaca 2880
aatgtctcgc tcgaacctgc tcctctgga ggaacagttc ttctgtccg gttgttacct 2940
cttctgtcgc gtctaggtcg gcgttgtgtt gcccgagagg tttggaccac aaccactggc 3000
tgagggcgct gagcgctcg tgtttgctg cgtggtcgtc ttcttcatt gataattctc 3060
ctacccacga ccgtatgcag atcgttcaaa catttgcaa taaagttct taagattgaa 3120
tctgttgcc ggtcttgca tgattatcat ataattctg ttgaattacg ttaagcatgt 3180
aataattaac atgtaatgca tgacgttatt tatgagatgg gttttatga ttagagttccc 3240
gcaattatac atttaatacg cgatagaaaa caaaatatag cgcgcaacct aggataaatt 3300
atcgcgcgog ggtcatceta tgttactaga tctctaga 3338

```

&lt;210&gt; 14

&lt;211&gt; 29

&lt;212&gt; DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: HiNK285

<400> 14

tcgtagaaga gaattcaccc aaactatcc

29

<210> 15

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: HiNK283

<400> 15

aagaattgca ggatccacag gctcggtac

29

<210> 16

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: HiNK284

<400> 16

ttccaacgaa ttcggtctca gaca

24

<210> 17

<211> 3648

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: pHiNK181

<220>

<221> promoter

<222> (1)..(1738)

<223> ubiquitin 3 promoter plus intron

<220>

<221> repeat\_unit

<222> (1739)..(2166)

<223> ENVV RNA1 repeat fragment

<220>

<221> misc\_feature

<222> (2167)..(2946)

<223> spacer fragment

<220>  
 <221> repeat\_unit  
 <222> (2947)..(3375)  
 <223> BNYV RNA1 repeat fragment

<220>  
 <221> stem\_loop  
 <222> (1739)..(3375)  
 <223> Inverted repeat of BNYV RNA1 fragment separated  
 by spacer

<220>  
 <221> terminator  
 <222> (3376)..(3648)  
 <223> NOS terminator

<400> 17  
 ggtaccggat ttggagccaa gtctcataaa cgccattgtg gaagaaagtc ttgagttggt 60  
 ggtaatgtaa cagagtagta agaacagaga agagagagag tgtgagatac atgaattgtc 120  
 gggcaacaaa aatcctgaac atcttatttt agcaaagaga aagagttccg agtctgtagc 180  
 agaagagtgga ggagaaattt aagctcttgg acttgtgaat tgttccgcct cttgaatact 240  
 tcttcaatcc tcatatattc ttcttctatg ttacctgaaa accggcattt aatctcgcgg 300  
 gtttattccg gttcaacatt ttttttgttt tgagttatta tctgggctta ataacgcagg 360  
 cctgaaataa attcaaggcc caactgtttt tttttttaag aagttgctgt taaaaaaaaa 420  
 aaaagggaat taacaacaac aacaaaaaaaa gataaagaaa ataataacaa ttactttaat 480  
 tgtagactaa aaaaacatag attttatcat gaaaaaaga gaaaagaaat aaaaacttgg 540  
 atcaaaaaaa aaaacatata gatcttctaa ttattaactt ttcttaaaaa ttaggtcctt 600  
 tttccaaca attaggttta gaggtttggg attaaacca aaagattggt ctaaaaata 660  
 ctcaaatttg gtagataagt ttcttattt taattagtca atggtagata ctttttttc 720  
 ttttctttat tagagtagat tagaatcttt tatgccaagt ttgataaat taaatcaaga 780  
 agataaacta tcataatcaa catgaaatta aaagaaaaat ctcatatata gtattagtat 840  
 tctctatata tattatgatt gcttattctt aatgggttgg gtaaccaag acatagtctt 900  
 aatggaaaga atcttttttg aactttttcc ttattgatta aattcttcta tagaaaagaa 960  
 agaaattatt tgaggaaaag tatatacaaa aagaaaaata gaaaaatgtc agtgaagcag 1020  
 atgtaattgga tgacctaatc caaccaccac cataggatgt ttctacttga gtcggtcttt 1080  
 taaaaacgca cggtggaataa tatgacacgt atcatatgat tccttccttt agtttcgtga 1140  
 taataatcct caactgatat cttccttttt ttgttttggc taaagatatt ttattctcat 1200  
 taatagaaaa gacggttttg ggcttttggg ttgcgatata aagaagacct tcgtgtggaa 1260  
 gataataatt catcctttcg tctttttctg actcttcaat ctctcccaa gcctaaagcg 1320  
 atctctgcaa atctctcgcg actctctctt tcaaggata tttcttgatt ctttttggtt 1380  
 ttgattcgta tctgatctcc aatttttggt atgtggatta ttgaatcttt tgtataaatt 1440  
 gcttttgaca atattgttcg tttcgtcaat ccagcttcta aattttgtcc tgattactaa 1500  
 gatatcgatt cgtagtgttt acatctgtgt aatttcttgc ttgatttga aattaggatt 1560  
 ttcaaggacg atctattcaa ttttttggtt ttctttgttc gattctctct gttttagggt 1620  
 tcttatgttt agatccgttt ctctttgggt ttgttttgat ttctcttacg gcttttgatt 1680  
 tggatatatg tcgctgattg gtttctactt gttctattgt tttatttcag gtggatccac 1740  
 aggctcggta cttatttcga aaagtgaaga attctccatc atcgacacaa gatagtgttg 1800  
 cacgtatggg tgctcagcta ttgtttctg attgtttggg gccaaatgta gctgatactt 1860  
 tttctgcttc caatttggtg cgaattatgg acaagctat gcatgacatg gtcgcaaaaa 1920  
 attaccaagg ccaaatggaa gaggagttaa cgcgtaatgc taaactatat cgttttcagt 1980  
 tgaaggatat tgaaaaacct ttgaaggacc cagagactga tttggcaaag gctggtaag 2040  
 ggatattggc atggtctaag gaggcacatg ttaagtttat ggttgctttt agagttttaa 2100  
 atgatttggt attgaagtca ttaactcta atgttgttta cgataacaca atgtctgaga 2160  
 ccgaattcac ccaaactatc ctcaacgggt ggcaatgaca taaaaacttc ccgtatcggg 2220  
 aacatcatca taaattgtc acgcccgtt cgagacacag agataatagc atccaaccaa 2280  
 cgttgaacat catcaacatt gcgacaagat aagctagcgt tacactccaa aaaatcagca 2340



```

taaacagctg ggtccttggg aagattttta atccaatcac gcaaagattc ctggtattca 2400
caaaaatgct tatactcacg gaacctgtgt gctgctatct tcgtcaattt acgcgaaaca 2460
cttggaacaa aatgtccatt agataaagca taaccacaaa aagtgatagg aacattttaa 2520
tccaatttga aatccaagac agtttctttt ttaatcaact ttaacatttg atcggttaatt 2580
ttcaaattag cctgcctttt aaaaccatca tcgcccttca tggccataca aaatgggtccg 2640
gtcccacgaa gcatagcatt taacatagca cccattaaaa tgggtattacc aagcaaagtg 2700
ccgggttctc cactagtctt aacataagac atatgtgtctc tgacatatct ggactgcata 2760
acatatttct cacgaaatga gaaataccaa tccaaaaaga agtcagaaat gcccaaagca 2820
gcataaatat gtctttctat caattgggtg aaaaccctt gcccagaatc gcaagcagca 2880
gcacogataa ccccgtttat agcactatct ggtactgtat tcatggcggc atttattttt 2940
ccaacaaatt cgggtctcaga cattgtgtta tcgtaaacaa cattagagtt taatgacttc 3000
aataacaaat cattttaaac tctaaaagca accataaact taacatgtgc ctcccttagac 3060
catgccaata tcccttgacc agcctttgcc aaatcagtct ctgggtcctt caaagggtttt 3120
tcaatatcct tcaactgaaa acgatatagt ttagcattac gcgtaaacct ctcttccatt 3180
tggccttggt aattttttgc gaccatgtca tgcatagtt tgtccataat tcgccacaaa 3240
ttggaagcag aaaaagtatc agctacattt ggcaccaaac aatcagaaac aaatagctga 3300
gcaaccatac gtgcaacact atcttgtgtc gatgatggag aatttctcac ttttcgaaat 3360
aagtaccgag cctgtggatc ccccgaaatt ccccgatcgt tcaaacattt ggcaataaag 3420
tttcttaaga ttgaatcctg ttgccggtct tgcgatgatt atcatctaatt ttctgttgaa 3480
ttacgttaag catgtaataa ttaacatgta atgcatgacg ttatttatga gatgggtttt 3540
tatgattaga gtcccgaat tatacattta atacgcgata gaaaacaaaa tatagcgcgc 3600
aaactaggat aaattatcgc gcgcggtgtc atctatgtta ctgatccc 3648

```

<210> 18

<211> 3648

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: pHINK184

<220>

<221> promoter

<222> (1)..(1738)

<223> ubiquitin 3 promoter plus leader intron

<220>

<221> repeat\_unit

<222> (1739)..(2166)

<223> BNYVV RNA1 repeat fragment

<220>

<221> misc\_feature

<222> (2167)..(2946)

<223> spacer

<220>

<221> repeat\_unit

<222> Complement((2947)..(3375))

<223> BNYVV RNA1 repeat fragment

<220>

<221> stem\_loop

<222> (1739)..(3375)

<223> Inverted repeat of BNYVV RNA1 fragment separated

by spacer

&lt;220&gt;

&lt;221&gt; terminator

&lt;222&gt; (3376)..(3648)

&lt;223&gt; NOS terminator

&lt;400&gt; 18

```

ggtaccggat ttggagccaa gtctcataaa cgccattgtg gaagaaagtc ttgagttggt 60
ggtaatgtaa cagagtagta agaacagaga agagagagag tgtgagatac atgaattgtc 120
gggcaacaaa aatcctgaac atcttatttt agcaaagaga aagagttccg agtctgtagc 180
agaagagtga ggagaaattt aagctcttgg acttgtgaat tgttccgcct cttgaatact 240
tcttcaatcc tcatatattc ttcttctatg ttacctgaaa accggcattt aatctcgcgg 300
gtttattccg gttcaacatt ttttttgttt tgagttatta tctgggctta ataacgcagg 360
cctgaaataa attcaaggcc caactgtttt tttttttaag aagttgctgt taaaaaaaa 420
aaaagggaat taacaacaac aacaaaaaaaa gataaagaaa ataataacaa ttactttaat 480
tgtagactaa aaaaacatag attttatcat gaaaaaaga gaaaagaaat aaaaacttgg 540
atcaaaaaaa aaacatata gatcttctaa ttattaactt ttcttaaaaa ttaggtcctt 600
tttcccaaca attaggttta gaggtttggg attaaaccaa aaagattgtt ctaaaaata 660
ctcaaatgtg gtagataagt ttcttatttt taattagtca atggtagata cttttttttc 720
ttttctttat tagagtagat tagaatcttt tatgccaaat ttgataaat taaatcaaga 780
agataaacta tcataatcaa catgaaatta aaagaaaaat ctcatatata gtattagtat 840
tctctatata tattatgatt gcttattctt aatgggttgg gttaaccaag acatagtctt 900
aatggaaaaga atcttttttg aactttttcc ttattgatta aattcttcta tagaaaagaa 960
agaaattatt tgaggaaaag tatatacaaa aagaaaaata gaaaaatgtc agtgaagcag 1020
atgtaatgga tgacctaatc caaccaccac cataggatgt ttctacttga gtcgggtctt 1080
taaaaacgca cgggtgaaaa tatgacacgt atcatatgat tcttctctt agtttcgtga 1140
taataatcct caactgatat ctctcttttt ttgttttggc taaagatatt ttattctcat 1200
taatagaaaa gacggttttg ggcttttggg ttgcgatata aagaagacct tcgtgtggaa 1260
gataataatt catcttttcg tctttttctg actcttcaat ctctcccaa gcctaaagcg 1320
atctctgcaa atctctcgcg actctctctt tcaaggata tttctgatt ctttttgttt 1380
ttgattcgta tctgatctcc aatttttgtt atgtggatta ttgaatcttt tgtataaatt 1440
gcttttgaca atattgttcg ttctgtcaat ccagcttcta aattttgtcc tgattactaa 1500
gatatcgatt cgtagtgttt acatctgtgt aatttcttgc ttgattgtga aattaggatt 1560
ttcaaggacg atctattcaa tttttgtgtt ttctttgttc gattctctct gtttttaggt 1620
tcttatgttt agatcgtttt ctctttgttg ttgttttgat ttctcttacg gcttttgatt 1680
tggtatatgt tcgctgattg gtttctactt gttctattgt tttatttcag gtggatccac 1740
aggctcggta cttatttcga aaagtgaaga attctccatc atcgacacaa gatagtgttg 1800
cacgtatggt tgctcagcta tttgtttctg attgtttggt gccaaatgta gctgatactt 1860
tttctgcttc caatttggg cgaattatgg acaaagctat gcatgacatg gtcgcaaaaa 1920
attaccaagg ccaaattggaa gaggagttta cgcgtaatgc taaactatat cgttttcagt 1980
tgaaggatat tgaaaaacct ttgaaggacc cagagactga ttgggcaaag gctggtcaag 2040
ggatattggc atggtctaag gaggcacatg ttaagtttat ggttgctttt agagttttaa 2100
atgatttgtt attgaagtca ttaactcta atgttgttta cgataacaca atgtctgaga 2160
ccgaatttgt tggaaaaata aatgcgcga tgaatacagt accagatagt gctataaacg 2220
gggttatcga tgctgctgct tgcgattctg ggcaaggggt ttccaccaa ttgatagaaa 2280
gacatattta tgctgctttg ggcattttct acttcttttt ggattggtat ttctcatttc 2340
gtgagaaata tgttatgcag tccagatatg tcagagcaca tatgtcttat gttaagacta 2400
gtggagaacc cggcactttg cttggttaata ccattttaat ggtgctatg ttaaatgcta 2460
tgcttcgttg gaccggacca ttttgatgg ccattgaagg cgtgatggt tttaaaaggc 2520
aggctaattt gaaaattaac gatcaaatgt taaagttgat taaaaaggaa actgtcttgg 2580
atttcaaatt ggatttaaat gttcctatca ctttttggg ttatgcttta tctaaggga 2640
ataagcattt ttgtgaatac caggaatctt tgcgtgattg gattaaaaat cttcccaag 2700
accagctgt ttatgctgat tttttggagt gtaacgctag cttatcttgt cgcaatgttg 2760
atgatgttca acgttggtg gatgctatta tctctgtgtc tcgaatcggg cgtgagcaat 2880

```

```

ttatgatgat gttcccgata cgggaagttt ttatgtcatt gccaccggtt gaggatagtt 2940
tgggtgaatt cgggtctcaga cattgtgtta tcgtaaacaa cattagagtt taatgacttc 3000
aataacaaat catTTaaaac tctaaaagca accataaact taacatgtgc ctcccttagac 3060
catgccaata tcccttgacc agcctttgcc aaatcagttc ctgggtcctt caaaggtttt 3120
tcaatatcct tcaactgaaa acgatatagt ttagcattac gcgtaaactc ctcttcatt 3180
tggccttggg aatTTTTtgc gaccatgtca tgcatagtt tgtccataat tgcgcacaaa 3240
ttggaagcag aaaaagtatc agctacattt ggcaccaaac aatcagaaac aaatagctga 3300
gcaaccatac gtgcaacact atcttgtgtc gatgatggag aatttctcac ttttcgaaat 3360
aagtaccgag cctgtggatc cccgaattt cccgatcgt tcaaacattt ggcaataaag 3420
tttcttaaga ttgaatcctg ttgccggtct tgcgatgatt atcatctaata ttctgttgaa 3480
ttacgttaag catgtaataa ttaacatgta atgcatgacg ttatttatga gatgggtttt 3540
tatgattaga gtcccgcaat tatacattta atacgcgata gaaaacaaaa tatagcgcg 3600
aaactaggat aaattatcgc gcgcggtgtc atctatgtta ctagatcc 3648

```

&lt;210&gt; 19

&lt;211&gt; 41

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: ZUP1563

&lt;400&gt; 19

ggcggatcc gctagccgc ggcggtctt tctttccaag g

41

&lt;210&gt; 20

&lt;211&gt; 35

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: ZUP1564

&lt;400&gt; 20

cccgccatgg gtcgacgcca ttttttatga gctgc

35

&lt;210&gt; 21

&lt;211&gt; 40

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: ZUP1565

&lt;400&gt; 21

cccgccatgg gatccgatga tttctaccga gaattaaggg

40

&lt;210&gt; 22

&lt;211&gt; 29

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

<220>  
<223> Description of Artificial Sequence: ZUP1566

<400> 22  
gggcgctagc ctaatgctta tatagtacc 29

<210> 23  
<211> 30  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: ZUP1567

<400> 23  
gggcgctagc cttgctggag tataagccgg 30

<210> 24  
<211> 35  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: ZUP1568

<400> 24  
gggcgtcgac cgcgggcttt aaaggtggga ggccc 35

<210> 25  
<211> 12766  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: pZU623

<220>  
<221> promoter  
<222> (55)..(1781)  
<223> ubiquitin3 promoter plus leader intron

<220>  
<221> misc\_feature  
<222> (1790)..(2430)  
<223> PRSV nt CP region

<220>  
<221> misc\_feature  
<222> (2511)..(3111)  
<223> ZYMV nt CP region

<220>  
<221> intron

<222> (3245)..(3686)  
<223> actin2 intronL

<220>  
<221> misc\_feature  
<222> Complement((3822)..(4422))  
<223> ZYMV nt CP region

<220>  
<221> misc\_feature  
<222> Complement((4503)..(5143))  
<223> PRSV nt CP region

<220>  
<221> terminator  
<222> (5160)..(5429)  
<223> NOS terminator

<220>  
<221> promoter  
<222> (5498)..(6669)  
<223> SMAS promoter

<220>  
<221> gene  
<222> (6691)..(7866)  
<223> phosphomannose isomerase A coding sequence

<220>  
<221> terminator  
<222> (7928)..(8202)  
<223> nopaline synthase terminator

<220>  
<221> misc\_feature  
<222> (8254)..(8385)  
<223> nopaline left border fragment

<220>  
<221> gene  
<222> (8664)..(9452)  
<223> spectinomycin (aadA) coding sequence

<220>  
<221> misc\_structure  
<222> (9462)..(11549)  
<223> pVS1 ORI

<220>  
<221> misc\_structure  
<222> (11550)..(12484)  
<223> pUC19 ORI

<220>  
<221> misc\_feature  
<222> (12500)..(12755)

<223> nopaline right border region

<220>

<221> stem\_loop

<222> (1790)..(5143)

<223> PRSV-ZYMV inverted repeat fragment

<400> 25

```

ggccgcagcg gccatttaaa tcaattgggc gcgccgaatt cgagctcggg accccggatt 60
tggagccaag tctcataaac gccattgttg aagaaagtct tgagttgggt gtaatgtaac 120
agagtagtaa gaacagagaa gagagagagt gtgagatata tgaattgtcg ggcaacaaaa 180
atcctgaaca tcttatttta gcaaagagaa agagttccga gtctgtagca gaagagttag 240
gagaaattta agctcttgga cttgtgaatt gtccgcctc ttgaatactt cttcaatcct 300
catatattct tcttctatgt tacctgaaaa ccggcattta atctcggggg tttattccgg 360
ttcaacattt tttttgtttt gagttattat ctgggcttaa taacgcaggc ctgaaataaa 420
ttcaaggccc aactgttttt ttttaagaa gtgtgtgta aaaaaaaaaa aagggaatta 480
acaacaacaa caaaaaaaga taaagaaaat aataacaatt actttaattg tagactaaaa 540
aacatagat tttatcatga aaaaaagaga aaagaaataa aaacttggat caaaaaaaaa 600
aacatacaga tcttctaatt attaatcttt cttaaaaatt aggtcctttt tccaacaat 660
taggtttaga gttttggaat taaacaaaa agattgttct aaaaaatact caaatttggg 720
agataagttt ccttatttta attagtcaat ggtagatact ttttttctt ttctttatta 780
gagtagatta gaatctttta tgccaagttt tgataaatta aatcaagaag ataaactatc 840
ataatcaaca tgaaattaaa agaaaaatct catatatagt attagtattc tctatatata 900
ttatgattgc ttattcttaa tgggttgggt taaccaagac atagtcttaa tggaaagaat 960
cttttttgaa ctttttctt attgattaaa ttctctata gaaaagaaag aaattatttg 1020
aggaaaagta tatacaaaa gaaaaataga aaaaatgtcag tgaagcagat gtaatggatg 1080
acctaattcca accaccacca taggatgttt ctacttgagt cgggtcttta aaaacgcacg 1140
gtggaaaata tgacacgtat catatgattc ctctcttag tttcgtgata ataactctca 1200
actgatatct tccttttttt gttttggcta aagatatttt attctcatta atagaaaaa 1260
cggttttggg cttttgggtt gcgatataaa gaagaccttc gtgtggaaga taataattca 1320
tcctttcgtc ttttttgac tcttcaatct ctccaaagc cttaaagcag ctctgcaaat 1380
ctctcgagc tctctctttc aaggtatatt ttctgattct ttttgttttt gattcgtatc 1440
tgatctccaa tttttgttat gtggattatt gaatcttttg tataaattgc ttttgacaat 1500
attgttcgtt tcgtcaatcc agcttctaaa ttttgcctg attactaaga tatcgattcg 1560
tagtgtttac atctgtgtaa tttcttgctt gattgtgaaa ttaggatttt caaggacgat 1620
ctattcaatt tttgtgtttt ctttgttoga ttctctctgt tttaggtttc ttatgtttag 1680
atccgtttct ctttgggtgt gttttgattt ctcttacggc ttttgatttg gtatatgttc 1740
gctgattggg ttctacttgt tctattgttt tatttcagggt gggggatccg atgatttcta 1800
ccgagaatta agggaaagac tgtccttaat ttaaatcatc ttcttcagta taatccgcaa 1860
caaattgaca tttctaacac tcgtgccact cagtcacaat ttgagaagtg gtatgaggga 1920
gtgaggaatg attatggtct caatgataat gaaatgcaag tgatgctaaa tggcttgatg 1980
gtttggtgta tcgagaatgg tacatctcca gacatatctg gtgtctgggt tatgatggat 2040
ggggaaaacc aagttgatta tccaatcaag cctttaatag agcatgtac tccgtcattt 2100
aggcaatta tggctcactt tagtaacgcg gcagaagcat acattgcgaa gagaaatgct 2160
actgagagat acatgccgcg gtatggaatc aagagaaatt tgactgacat tagtcttgct 2220
agatacgctt tcgacttcta tgaggtgaat tcgaaaacac ctgatagggc tcgtgaagct 2280
cacatgcaga tgaaagctgc agcgtgcga aacactagtc gcagaatgtt tggatgggac 2340
ggcagtggtt gtaacaagga agaaaacacg gagagacaca cagtgggaaga tgtcaataga 2400
gacatgcact ctctcctggg tatgcgcaac tgaatactcg cgcttggttg tttgtcgagt 2460
ctgactcgac cctgtttcac cttatggtac tatataagca ttaggctagc cttgtcggag 2520
tataagccgg atcaaattga gttatacaac acacgagcgt ctcatcagca attcgcctct 2580
tgyttcaacc aagttaaaac agaatatgat ctgaatgagc aacagatggg agttgtaatg 2640
aatggtttca tggtttggtg cattgaaaat ggcacgtcac ccgacattaa cggagtatgg 2700
gttatgatgg acggtaatga gcaggttgaa tatcctttga aaccaatagt tgaaaatgca 2760
aagccaacgc tgcgacaaat aatgcatcac ttttcagatg cagcggaggc atatatagag 2820
atgagaaatg cagaggcacc atacatgccg aggtatgggt tgcttcgaaa cttacgggat 2880

```

```

aggagtttgg caccgatatgc tttcgacttc tacgaagtca attccaaaac tccggaaaga 2940
gccgcggaag ctgttgcgca gatgaaagca gcagccctta gcaatgtttc ttcaagggtg 3000
tttggccttg atggaaatgt tgccaccact agcgaagaca ctgaacggca cactgcacgt 3060
gatgttaata ggaacatgca cacccttgcta ggtgtgaata caatgcagta aagggttaggt 3120
cgctaccta gggtatcggt tcgctgccga cgtaatctta atatttaccg ctttatgtga 3180
tgtctttaga tttctagagt gggcctccca cctttaaaagc ccgcggccgc tctttcttcc 3240
caaggttaata ggaactttct ggatctactt tatttgctgg atctcgatct tgttttctca 3300
atttccttga gatctggaat tcgtttaatt tggatctgtg aacctccact aaatcctttg 3360
gttttactag aatcgatcta agttgaccga tcagttagct cgattatagc taccagaatt 3420
tggcttgacc ttgatggaga gatccatggt catgttacct gggaaatgat ttgtatatgt 3480
gaattgaaat ctgaactggt gaagttagat tgaatctgaa cactgtcaat gttagattga 3540
atctgaacac tgtttaagtt agatgaagtt tgtgtataga ttcttcgaaa ctttaggatt 3600
tgtagtgtcg tacgttgaac agaaagctat ttctgattca atcagggttt atttgactgt 3660
attgaactct ttttgtgtgt ttgcagctca taaaaaatgg cgtcgaccgc gggctttaaa 3720
gggtgggagg ccactctaga aatctaaaga catcacataa agcggtaaat attagaatta 3780
cgctggcagc gaaacgataa cctaggtagg cgacctacc tttactgcat tgtattcaca 3840
cctagcaagg tgtgcatggt cctattaaca tcaogtgcag tgtgccgttc agtgtcttcg 3900
ctagtgggtg caacatttcc atcaaggcca aacaaccttg aagaaacatt gctaagggtc 3960
gctgctttca tctgcgcaac agcttcgagg gctctttccg gagttttgga attgacttcg 4020
tagaagtcca aagcatatcg tgccaaactc ctatcccgta agtttcgaag caaacatac 4080
ctcggcatgt atgggtgcctc tgcatttctc atctctatat atgcctccgc tgcactgaa 4140
aagtgatgca tttttgtcg cagcgttggc tttgcatttt caactattgg tttcaaagga 4200
tattcaacct gtcattacc gtccatcata acccactatc cgttaatgtc gggtgacgtg 4260
ccattttcaa tgcaccaaac catgaaacca ttcatatac ctccatctg ttgctcattc 4320
agatcatatt ctgttttaac ttggttgaa caagaggcga attgctgatg agacgctcgt 4380
gtgtgtata actcaatttg atccggtta tactccagca aggttagcct aatgcttata 4440
tagtaccata aggtgaaaca gggtcgagtc agactcgaca aacacacaag ccgaggtatt 4500
cagttgcgca taccaggag agagtgcag tctctattga catcttcac tgtgtgtctc 4560
tccgtgtttt ctctctgtt actaacactg ccgtccatac caaacattct gcgactagt 4620
tttcgcagcg ctgcagcttt catctgcatg tgagcttcac gagccctatc aggtgttttc 4680
gaattcaacct catagaagtc gaaagcgtat ctgcaagac taatgtcagt caaatttctc 4740
ttgattccat acccgggcat gtatctctca gtagcatttc tcttcgcaat gtatgcttct 4800
gccgcgttac taaagtgagc cataatttgc ctaaagacg gagtagcatg ctctattaaa 4860
gggttgattg gataatcaac ttgggtttcc ccatccatca taaccagac accagatag 4920
tctggagatg taccattctc gatacaccaa accatcaagc catttagcat cacttgcat 4980
tcattatcat tgagaccata atcattctc actccctcat accattctc aaattgtgac 5040
tgagtggcac gagtgttaga aatgtcaatt tgttgcggat tatactgaag aagatgattt 5100
aaattaagga cagtctttcc cttaattctc ggtagaaatc atcgatcca tgggtatcac 5160
tgcagatcgt tcaaacattt ggcaataaag tttcttaaga ttgaatcctg ttgccggtct 5220
tgcgatgatt atcatataat ttctgttgaa ttacgttaag catgtaataa ttaacatgta 5280
atgcatgacg ttattttatga gatgggtttt tatgattaga gtcccgcaat tatacattta 5340
ataccgata gaaaacaaaa tatagcgcgc aaactaggat aaattatcgc gcgcggtgtc 5400
atctatgtta ctatgctct agaaagcttc gtacgttaat taattcgaat ccggagcggc 5460
cgcagggtta gcatcgatgg taccgagctc gagactatac aggcctaat cgctcttagc 5520
cgtacaatat tactcacggg tgcgatgccc cccatcgtag gtgaagggtg aaattaatga 5580
tccatcttga gaccacagc ccacaacagc taccagttc ctcaagggtc caccaaaaac 5640
gtaagcgtt acgtacatgg tcgataagaa aaggcaattt gtagatgtta acatccaacg 5700
tcgctttcag ggatcccga tccaagctt ggaattcggg atcctacagg ccaaattcgc 5760
tcttagccgt acaatattac tcaccggtgc gatgcccccc atcgtagggtg aagggtgaaa 5820
ttaatgatcc atcttgagac cacaggccca caacagctac cagtttctc aagggtccac 5880
caaaaacgta agcgttacg tacatggtcg ataagaaaag gcaatttgta gatgttaaca 5940
tccaacgtcg cttcaggga tcccgatctc caagcttggg attcgggac ctacaggcca 6000
aattcgtct tagccgtaca atattactca ccggtgcgat ccccccacg taggtgaagg 6060
tgaaattaa tgatccatct tgagaccaca ggcccacaac agctaccagt ttctcaagg 6120
gtccacaaa aacgtaagcg cttacgtaca tggtcgataa gaaaaggcaa tttgtagatg 6180
ttaacatcca acgtcgttt cagggtatccc gaattccaag cttgggctgc aggtcaatcc 6240

```

cattgctttt gaagcagctc aacattgatc tctttctoga gggagatttt tcaaatcagt 6300  
gcgcaagacg tgacgtaagt atccgagtc gtttttattt ttctactaat ttggctgctt 6360  
atttcggcgt gtaggacatg gcaaccgggc ctgaatttcg cgggtattct gtttctattc 6420  
caactttttc ttgatccgca gccattaacg acttttgaat agatacgtg acacgccaa 6480  
cctcgctagt caaaagtgt ccaaacaacg ctttacagca agaacggaat gcgcgtgacg 6540  
ctcgcggtga cgccatttcg ctttttcaga aatggataaa tagccttgct tcctattata 6600  
tcttcccaaa ttaccaatac attacactag catctgaatt tcataaccaa tctcgatata 6660  
ccaaatcgag atctgcaggg atccccgatc atgcaaaaac tcattaactc agtgcaaaaac 6720  
tatgcctggg gcagcaaaaac ggcgttgact gaactttatg gtatggaaaa tccgtccagc 6780  
cagccgatgg ccgagctgtg gatggcgca catcogaaaa gcagttcacg agtgcagaat 6840  
gccgcggag atatogtttc actgctgat gtgattgaga gtgataaaat gactctgctc 6900  
ggagagggcg ttgccaacg ctttggcgaa ctgcctttcc tgttcaaagt attatgcgca 6960  
gcacagccac tctccattca ggttcatcca acaaacaca attctgaaat cggttttgcc 7020  
aaagaaaatg ccgcaggtat cccgatggat gccgcggagc gtaactataa agatcctaac 7080  
cacaagccgg agctggtttt tgcgctgacg cttttccttg ogatgaacgc gtttctgtga 7140  
ttttccgaga ttgtctccct actccagccg gtccgaggtg cacatccggc gattgtctac 7200  
tttttacaac agcctgatgc cgaacgttta agcgaactgt tccgcagcct gttgaatatg 7260  
caggggtgaag aaaaaatccc gcgcgtggcg attttaaaat cggccctcga tagccagcag 7320  
ggtgaaccgt ggcaaacgat tcgtttaatt tctgaatttt acccggaaga cagcggctcg 7380  
ttctccccgc ttatgtgtaa tgtggtgaaa ttgaaccctg gcgaagcgat gttcctgttc 7440  
gctgaaacac cgcacgctta cctgcaaggc gtggcgctgg aagtgtggc aaactccgat 7500  
aacgtgctgc gtgcgggtct gacgcctaaa tacattgata ttccggaact ggttgccaat 7560  
gtgaaattcg aagccaaacc ggctaaccag ttgttgaccc agccggtgaa acaaggtgca 7620  
gaactggact tcccgatcc agtgatgat tttgccttct cgtgcatga ccttagtgat 7680  
aaagaaacca ccattagcca gcagagtgcc gccattttgt tctgcgtcga agcgatgca 7740  
acgttgtgga aaggttctca gcagttacag cttaaacccg gtgaatcagc gtttattgcc 7800  
gccaaacgaat caccggtgac tgtcaaaggc caccggcgtt tagcgcgtgt ttacaacaag 7860  
ctgtaagagc ttactgaaaa aattaacatc tcttgctaag ctgggagctc gtcgacggat 7920  
cgaattcctg cagatcgttc aaacatttgg caataaagtt tcttaagatt gaatcctgtt 7980  
gccggtcctg cgtatgattat catataattt ctgttgaatt acgttaagca tgtaataatt 8040  
aacatgtaat gcatgacgtt atttatgaga tgggttttta tgattagagt cccgcaatta 8100  
tacatttaat acgcgataga aaacaaaata tagcgcgcaa actaggataa attatcgcg 8160  
gcggtgtcat ctatgttact agatctctag aactagtggg tctgctagcc ctgcaggaaa 8220  
tttacgggtg cccggggcggc cagcatggcc gtatccgcaa tgtgttatta agttgtctaa 8280  
gcgtcaattt gtttacacca caatatatcc tgccaccagc cagccaacag ctccccgacc 8340  
ggcagctcgg cacaaaatca ccactcgata caggcagccc atcagaatta attctcatgt 8400  
ttgacagctt atcatcgact gcacggtgca ccaatgcttc tggcgctcag cagccatcgg 8460  
aagctgtggt atggctgtgc aggtcgtaaa tcaactgcata attcgtgtcg ctcaaggcgc 8520  
actcccgctt tggataatgt tttttgogcc gacatcataa cgggtctggc aaatattctg 8580  
aaatgagctg ttgacaatta atcatcggtc cgtataatgt gtggaattgt gagcggataa 8640  
caatttcaca caggaaacag accatgaggg aagcgggtgat cgcgaagta tcgactcaac 8700  
tatcagaggt agttggcgct atcgagcgcc atctogaacc gacgttgctg gccgtacatt 8760  
tgtacggctc cgcagtggtt ggoggcctga agccacacag tgatattgat ttgctgggta 8820  
cggtgaccgt aaggcttgat gaaacaacgc ggcgagcttt gatcaacgac cttttggaaa 8880  
cttcggcttc cctggagag agcagatttc tccgcgctgt agaagtcacc attgtgtgct 8940  
acgacgacat cattccgtgg cgttatccag ctaagcgcca actgcaattt ggagaatggc 9000  
agcgcaatga cattcttgca ggtatcttcg agccagccac gatcgacatt gatctggcta 9060  
tcttgctgac aaaagcaaga gaacatagcg ttgccttggt aggtccagcg gcggaggaa 9120  
tctttgatcc ggttcttgaa caggatctat ttgaggcgct aaatgaaacc ttaacgctat 9180  
ggaaactcgc gcccgactgg gctggcgatg agcgaaatgt agtgcttacg ttgtcccga 9240  
tttggtacag cgcagtaacc ggcaaaatcg cgcogaagga tgcgctgcc gactgggcaa 9300  
tggagcgctt gccggcccag tatcagcccg tcatacttga agctaggcag gcttatcttg 9360  
gacaagaaga togtttggcc tgcgcgcgag atcagttgga agaatttgtt cactacgtga 9420  
aaggcgagat caccaaggta gtccgcaaat aaagctctag tggatccccg aggaatcggc 9480  
gtgacggctg caaacatcc ggcccggtac aaatcgcgcg ggcgctgggt gatgacctgg 9540  
tggagaaggt gaaggccgcg caggccgccc agcggcaacg catcgaggca gaagcacgcc 9600



```

ccggtgaatc gtggcaagcg gccgctgac gaatccgcaa agaatcccgg caaccgccgg 9660
cagccgggtgc gccgtcgatt aggaagccgc ccaagggcga cgagcaacca gattttttcg 9720
ttccgatgct ctatgacgtg ggcaaccgcg atagtcgcag catcatggac gtggccgttt 9780
tccgtctgtc gaagcgtgac cgacgagctg gcgaggtgat ccgctacgag cttccagacg 9840
ggcacgtaga ggtttcagca gggccggccg gcatggccag tgtgtgggat tacgacctgg 9900
tactgatggc ggtttcccat ctaaccgaat ccatgaaccg ataccgggaa gggaagggag 9960
acaagcccgg ccgctgtgtc cgtccacacg ttgcggacgt actcaagttc tgccggcgag 10020
ccgatggcgg aaagcagaaa gacgacctgg tagaaacctg cattcggtta aacaccacgc 10080
acgttgccat gcagcgtacg aagaaggcca agaacggccg cctggtgacg gtatccgagg 10140
gtgaagcctt gattagccgc tacaagatcg taaagagcga aaccggcgcg ccggagtaca 10200
tcgagatcga gctagctgat tggatgtacc gcgagatcac agaaggcaag aaccggcgag 10260
tgctgacggg tcaccccgat tactttttga tcgatcccgg catcgccggt tttctctacc 10320
gcctggcagc ccgcccgcga ggcaaggcag aagccagatg gttgttcaag acgatctacg 10380
aacgcagtgg cagcgccgga gagttcaaga agttctgttt caccgtgcgc aagctgatcg 10440
ggtcaaataa cctgccggag tacgatttga aggaggaggc ggggcaggct ggcccgatcc 10500
tagtcatgcg ctaccgcaac ctgatcgagg gcgaagcatc ccgcygttcc taatgtacgg 10560
agcagatgct agggcaaat gcccctagcag gggaaaaagg tcgaaaagggt ctctttcctg 10620
tggatagcac gtacattggg aacccaaagc cgtacattgg gaaccggaac ccgtacattg 10680
ggaacccaaa gccgtacatt gggaaccggg cacacatgta agtgactgat ataaaagaga 10740
aaaaaggcga tttttccgcc taaaactctt taaaactctt taaaactctt aaaacccgcc 10800
tggcctgtgc ataactgtct ggccagcgca cagccgaaga gctgcaaaaa gcgcctacc 10860
ttcggctcgt gcgtcccta cggcccgccg cttcgcgtcg gcctatcgcg gccgtggcc 10920
gctcaaaaat ggctggccta cggccaggca atctaccagg gcgcggacaa gccgcgccgt 10980
cgccactcga ccgcccggcg tgaggtctgc ctctgaaga aggtgttgc gactcatacc 11040
aggcctgaat cggcccatca tccagccaga aagtgaggga gccacggttg atgagagctt 11100
tgtttaggtt ggaccagttg gtgattttga acttttgcct tgccacggaa cgtctgcgt 11160
tgtcgggaag atgcgtgatc tgatccttca actcagcaaa agttcgattt attcaacaaa 11220
gccgcgctcc cgtcaagtca gcgtaatgct ctgccagtgt tacaaccaat taaccaattc 11280
tgattagaaa aactcatcga gcatcaaatg aaactgcaat ttattcatat caggattatc 11340
aataccatat ttttgaaaaa gccgtttctg taatgaagga gaaaactcac cgaggcagtt 11400
ccataggatg gcaagatcct ggtatcggtc tgcgattccg actcgtccaa catcaatata 11460
acctattaat ttccctcgt caaaaataag gttatcaagt gagaaatcac catgagtac 11520
gactgaatcc ggtgagaatg gcaaaagctc tgcattaatg aatcggccaa ccgcccggga 11580
gaggcggttt gcgtattggg cgtctctccg cttcctcgt cactgactcg ctgcgtcgg 11640
tcgttcggct gcggcgagcg gtatcagctc actcaaaggc ggtaatacgg ttatccacag 11700
aatcagggga taacgcagga aagaacatgt gagcaaaagg ccagcaaaag gccaggaacc 11760
gtaaaaaggc ccggttgctg gcgtttttcc ataggctccg cccctctgac gagcatcaca 11820
aaaaatcgac ctcaagtcag aggtggcgaa acccgacagg actataaaga taccaggcgt 11880
ttccctcgtg aagctccctc gtgcgtctc ctgttccgac cctgcgctt accggatacc 11940
tgtccgcctt tctccctcgt ggaagcgtgg cgttttctca atgctcacgc ttaggtatc 12000
tcagttcggg taggtcgtt cgtccaagc tgggctgtgt gcacgaaccc ccggttcagc 12060
ccgaccgctg cgccttatcc ggttaactat gtcttgagtc caaccggta agacacgact 12120
tatcgccact ggcagcagcc actggtaaca ggattagcag agcgaggat gtaggcggtg 12180
ctacagagtt cttgaagtgg tggcctaact acggctacac tagaaggaca gtatttggtg 12240
tctgcgtctc gctgaagcca gttacctcgt gaaaaagagt tggtagctct tgatccggca 12300
aacaaccac ccgtggtagc ggtggttttt ttgtttgcaa gcagcagatt acgcgagaa 12360
aaaaaggatc tcaagaagat cctttgatct tttctacggg gtctgacgct cagtggacg 12420
aaaactcacg ttaagggtt ttggtcatga gattatcaaa aaggatctt accatagatc 12480
ttttgatccg gaattaattc ctgtggttgg catgcacata caaatggagc aacggataaa 12540
ccttttcacg cccttttaaa tatccgatta ttctaataaa cgtcttttct tcttaggttt 12600
accgcaccaat atatcctgtc aaacactgat agtttaaact gaaggcgga aacgacaatc 12660
tgatcatgag cggagaatta agggagtcac gttatgaccc ccgccgatga ccggggacaa 12720
gccgttttac gtttggaact gacagaaccg caacgctgca ggaatt 12760

```

<211> 42  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: ZUP1598

<400> 26  
catgccatgg atccaatggc cacgaattaa agctatcacg tc

42

<210> 27  
<211> 44  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: ZUP1590

<400> 27  
acgcgtcgac cgcggattca aacgattatt aattacgata aaag

44

<210> 28  
<211> 11461  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: pZU634

<220>

<221> promoter

<222> (55)..(1786)

<223> ubiquitin3 promoter plus leader intron

<220>

<221> misc\_feature

<222> (1790)..(2574)

<223> PVY nt CP region

<220>

<221> intron

<222> (2595)..(3036)

<223> actin2 intronL

<220>

<221> misc\_feature

<222> Complement((3057)..(3847))

<223> PVY nt CP region

<220>

<221> terminator

<222> (3855)..(4124)

<223> NOS terminator

```

<220>
<221> promoter
<222> (4193)..(5364)
<223> SMAS promoter

<220>
<221> gene
<222> (5386)..(6561)
<223> phosphomannose isomerase A coding sequence

<220>
<221> terminator
<222> (6623)..(6897)
<223> nopaline synthase terminator

<220>
<221> misc_feature
<222> (6949)..(7080)
<223> nopaline left border fragment

<220>
<221> gene
<222> (7359)..(8147)
<223> spectinomycin (aadA) coding sequence

<220>
<221> misc_structure
<222> (8157)..(10244)
<223> pVS1 ORI

<220>
<221> misc_structure
<222> (10245)..(11179)
<223> pUC19 ORI

<220>
<221> misc_feature
<222> (11195)..(11450)
<223> nopaline right border region

<220>
<221> stem_loop
<222> (1790)..(3847)
<223> PVY inverted repeat region

<400> 28
ggccgcagcg gccatttaaa tcaattgggc ggcgcgaatt cgagctcggc acccgtaccg 60
gatttggagc caagtctcat aaacgccatt gtggaagaaa gtcttgagtt ggtggtaatg 120
taacagagta gtaagaacag agaagagaga gagtgtgaga tacatgaatt gtcgggcaac 180
aaaaatcctg aacatcttat tttagcaaag agaaagagtt ccgagtcctgt agcagaagag 240
tgaggagaaa ttaagctctt tggacttgtg aattgttccg cctcttgaat acttcttcaa 300
tcctcatata ttcttcttct atgttacctg aaaaccggca ttaatactcg cgggtttatt 360
cgggttcaac attttttttg ttttgagtta ttatctgggc ttaataacgc aggcctgaaa 420
taaatcaag gcccaactgt tttttttttt aagaagttgc tgtaaaaaaa aaaaaaaggg 480
aattaacaac aacaacaaaa aaagataaag aaaataataa caattacttt aattgtagac 540
taaaaaaaca tagattttat catgaaaaaa agagaaaaga aataaaaact tggatcaaaa 600

```

```

aaaaaacat acagatcttc taattattaa cttttcttaa aaattaggtc ctttttccca 660
acaattaggt tttagagtttt ggaattaaac caaaaagatt gttctaaaaa atactcaaat 720
ttggttagata agtttcctta ttttaattag tcaatggtag atactttttt ttcttttctt 780
tattagagta gattagaatc ttttatgcca agttttgata aattaaatca agaagataaa 840
ctatcataat caacatgaaa ttaaaagaaa aatctcatat atagtattag tattctctat 900
atatattatg attgcttatt cttaatgggt tgggttaacc aagacatagt cttaatggaa 960
agaatctttt ttgaactttt tccttattga ttaaattctt ctatagaaaa gaaagaaatt 1020
at ttgaggaa aagtataac aaaaagaaaa atagaaaaat gtcagtgaag cagatgtaat 1080
ggatgacctt atccaaccac caccatagga tgtttctact tgagtcggtc ttttaaaaac 1140
gcacgggtgga aaatatgaca cgtatcatat gattccttcc tttagtttcg tgataataat 1200
cctcaactga tatcttcctt tttttgtttt ggctaaagat attttattct cattaataga 1260
aaagacgggt ttgggctttt ggtttgcgat ataaagaaga ctttcgtgtg gaagataata 1320
attcatcctt tcgtcttttt ctgactcttc aatctctccc aaagcctaaa gcgactctctg 1380
caaatctctc gcgactctct ctttcaagggt atattttctg attctttttg tttttgattc 1440
gtatctgac tcgaattttt gttatgtgga ttattgaatc ttttgataaa attgcttttg 1500
acaatattgt tcgtttcgtc aatccagctt ctaaattttg tcctgattac taagatatcg 1560
attcgtagtg tttacatctg tgtaatttct tgcttgattg tgaatttagg attttcaagg 1620
acgactctatt caatttttgt gttttctttg ttgacttctc tctgttttag gtttcttatg 1680
tttagatccg tttctctttg gtgttgtttt gatttctctt acggcttttg atttgggata 1740
tgttcgtgta ttggtttcta cttgttctat tgttttattt caggtggggg atccaatggc 1800
cacgaattaa agctatcacg tccaaaatga gaatgccaa gagtaagggt gcaactgtac 1860
taaatttgga acacctactc gagtatgtct cacagcaaat tgaatctca aatactcgag 1920
caactcaatc acagtttgat acatgggatg aagcagtaca acttgcatc gacataggag 1980
aaactgaaat gccaaactgt atgaatgggc ttatgggttg gtgcattgaa aatggaacct 2040
cgccaaatat caatggagtt tgggttatga tggatggaga tgaacaagtc gaataccac 2100
tgaaaccaat cgttgagaat gcaaaacca cacttaggca aatcatggca catttctcag 2160
atgttgacga agcgtatata gaaatgcgca aaaaaagga accatatatg ccacgatatg 2220
gttttagttc taatctgcgc gatggaagtt tggctcgcta tgcttttgac ttttatgaag 2280
ttacatcacg tacaccagtg agggctagag aggcacacat tcaaatgaag gccgcagctt 2340
taaaatcacg tcaatctcga cttttcggtt tggatgggtg cattagtaca caagaggaaa 2400
acacagagag gcacaccacc gaggatgttt ctccaagtat gcatactcta cttggagtga 2460
agaacatgtg attgtagtgt ctttcgggac gatatataga tatttatgtt tgcagtgaag 2520
at ttgtggtt ttctgtact acttttatcg taattaataa tcgtttgaat ccgcggccgc 2580
tctttctttc caaggtaata ggaactttct ggactactt tatttgcgtg atctcgatct 2640
tgttttctca atttcttga gatctggaat tcgtttaatt tggatctgtg aacctccact 2700
aaatcttttg gttttactag aatcgatcta agttgaccga tcagttagct cgattatagc 2760
taccagaatt tggcttgacc ttgatggaga gatccatgtt catgttacct gggaaatgat 2820
ttgtatatgt gaattgaaat ctgaactgtt gaagttagat tgaatctgaa cactgtcaat 2880
gttagattga atctgaacac tgtttaagtt agatgaagtt tgtgtataga ttcttcgaaa 2940
ctttaggatt tgtagtgtcg tacgttgaa agaaagctat ttctgattca atcagggttt 3000
at ttgactgt attgaactct ttttgtgtgt ttgcagctca taaaaaatgg cgtcgaccgc 3060
ggattcaaac gattattaat tacgataaaa gtagtacagg aaaagccaaa atacttactg 3120
caaacataaa tatctatata tcgtccggaa agacactaca atcacatgtt cttactcca 3180
agtagagtat gcatacttgg agaaacatcc tcggtgggtg gcctctctgt gttttctct 3240
tgtgtactaa tgccaccatc caatccgaaa agtcgagatt gagctgattt taaagctcg 3300
gccttcattt gaatgtgtgc ctctctagcc ctactgggtg tacgtgatgt aacttcataa 3360
aagtcaaaag catagcgagc caaacttcca tcgcgcagat tacgaactaa accatatcgt 3420
ggcatatatg gttccttttt gtgogcatt tctatatacg cttctgcaac atctgagaaa 3480
tgtgccatga tttgcctaag tgttggtttt gcattctcaa cgattgggtt cagtggttat 3540
tcgacttggt catctccatc catcataacc caaactccat tgatatttgg cgaggttcca 3600
ttttcaatgc accaaacatc aagcccatc atcacagttg gcaattcagt ttctcctatg 3660
tcgtatgcaa gttgtactgc ttcataccat gtatcaaact gtgattgagt tgctcgagta 3720
tttgagattt caatttgctg tggagcatc tcgagtaggt gttccaaatt tagtacagtt 3780
gcacccttac tcttggcat tctcattttg gacgtgatag ctttaattcg tggccattgg 3840
atccatgggt atcactgcag atcgttcaaa catttggtgaa taaagtttct taagattgaa 3900
tcctgttgcc ggtcttgcca tgattatcat ataatttctg ttgaattacg ttaagcatgt 3960

```

aataattaac atgtaatgca tgacgttatt tatgagatgg gtttttatga ttagagtccc 4020  
gcaattatac atttaatacg cgatagaaaa caaaatatag cgcgcaacct aggataaatt 4080  
atcgcgcgcg gtgtcatcta tgttactaga tctctagaaa gcttcgtacg ttaattaatt 4140  
cgaatccgga gcgcccgag ggctagcatc gatggtagcg agctcgagac tatacaggcc 4200  
aaattcgctc ttagccgtac aatattactc accgggtgca tgccccccat cgtaggtgaa 4260  
ggtagaaatt aatgatccat cttgagacca caggcccaca acagctacca gtttccctcaa 4320  
gggtccacca aaaacgtaag cgcttacgta catggtagat aagaaaagc aattttaga 4380  
tgtaaacatc caacgtcgct ttcagggatc ccgaattcca agcttggaat tcgggatcct 4440  
acaggccaaa ttcgctctta gccgtacaat attactcacc ggtgcatgac ccccatcgt 4500  
aggtgaaggt ggaaattaat gatccatctt gagaccacag gccacaaca gctaccagtt 4560  
tcctcaaggg tccaccaaaa acgtaagcgc ttacgtacat ggtcgataag aaaagcaat 4620  
ttgtagatgt taacatccaa cgtcgctttc agggatcccg aattccaagc ttggaattcg 4680  
ggatcctaca ggccaaattc gctcttagcc gtacaatatt actcaccggt gcgatcccc 4740  
catcgtaggt gaaggtggaa attaatgatc catcttgaga ccacaggccc acaacagcta 4800  
ccagtttctc caaggggtcca ccaaaaacgt aagcgcttac gtacatggtc gataagaaaa 4860  
ggcaatttgt agatgttaac atccaacgct gctttcaggg atcccgaatt ccaagcttg 4920  
gctgcaggtc aatcccattg cttttgaagc agctcaacat tgatctcttt ctcgaggag 4980  
atttttcaaa tcagtgcgca agacgtgacg taagtatccg agtcagtttt tatttttcta 5040  
ctaatttggg cgtttatttc ggctgttagg acatggcaac cgggctgaa ttctcggggt 5100  
attctgtttc tattccaact tttcttgat ccgcagccat taacgacttt tgaatagata 5160  
cgctgacacg ccaagcctcg ctagtcaaaa gtgtacaaa caacgcttta cagcaagaa 5220  
ggaatgcgcg tgacgtctcg ggtgacgcca ttctgccttt tcagaaatgg ataaatagcc 5280  
ttgcttctta ttatatcttc ccaattacc aatacattac actagcatct gaatttcata 5340  
accaatctcg atacacaaaa tcgagatctg cagggatccc cgatcatgca aaaactcatt 5400  
aactcagtcg aaaactatgc ctggggcagc aaaaacggcg tgactgaact ttatggtatg 5460  
gaaaatccgt ccagccagcc gatggccgag ctgtggatgg gcgcacatcc gaaaagcagt 5520  
tcacgagtcg agaatgcgcg cggagatata gtttcactgc gtgatgtgat tgagagtgat 5580  
aaatcgactc tgctcgaga ggccgttgcc aaacgctttg gcgaactgcc ttctctgttc 5640  
aaagtattat gcgcagcaca gccactctcc attcaggttc atccaaacaa acacaattct 5700  
gaaatcggtt ttgccaaaga aaatgcgca ggtatcccga tggatgccgc cgagcgtaac 5760  
tataaagatc ctaaccacaa gccggagctg gtttttgcgc tgacgccttt ccttgcatg 5820  
aacgcgtttc gtgaattttc cgagattgtc tcctactcc agccggtcgc aggtgcacat 5880  
ccggcgattg ctactttttt acaacagcct gatgccgaac gtttaagcga actgttcgcc 5940  
agcctgttga atatgcaggg tgaagaaaaa tccgcgcgcg tggcgatttt aaaatcgcc 6000  
ctcagtagcc agcaggggtga accgtggcaa acgattcgtt taatttctga attttaccg 6060  
gaagacagcg gtctgttctc ccgcgtattg ctgaatgtgg tgaaattgaa ccttggcgaa 6120  
gcgatgttcc tgttcgtgta aacaccgcac gcttacctgc aaggcgtggc gctggaagt 6180  
atggcaaaact ccgataacgt gctgcgtgcg ggtctgacgc cttaaatacat tgatattccg 6240  
gaactggttg ccaatgtgaa attcgaagcc aaaccggcta accagttgtt gaccagccg 6300  
gtgaaacaag gtgcagaact ggacttcccg attccagtg atgattttgc cttctcgctg 6360  
catgacctta gtgataaaga aaccaccatt agccagcaga gtgccgccat ttgttctgc 6420  
gtcgaaggcg atgcaacggt gtggaaagg tctcagcagt tacagcttaa accgggtgaa 6480  
tcagcgttta ttgccgcaa cgaatcaccg gtgactgtca aaggccacgg ccgttttagc 6540  
cgtgtttaca acaagctgta agagcttact gaaaaaatta acatctcttg ctaagctggg 6600  
agctcgtcga cggatcgaat tcctgcagat cgttcaaaca tttggcaata aagtttctta 6660  
agattgaatc ctgttgccgg tcttgcatg attatcatat aatttctgtt gaattacgtt 6720  
aagcatgtaa taattaacat gtaatgcatg acgttattta tgagatgggt ttttatgatt 6780  
agagtcccg aattatacat ttaatacgc atagaaaaca aaatatagcg cgcaaactag 6840  
gataaattat cgcgcgcggg gtcactatg ttactagatc tctagaacta gtggatctgc 6900  
tagccctgca ggaattttac cgggtgcccg gcggccagca tggcgcgtat cgcaatgtgt 6960  
tattaagttg tctaagcgtc aatttgttta caccacaata tatcctgcca ccagccagcc 7020  
aacagctccc cgaccggcag ctccgcacaa aatcaccact cgatacagc agcccatcag 7080  
aattaattct catgtttgac agcttatcat cgactgcacg gtgcaccaat gcttctggcg 7140  
tcaggcagcc atcgggaagc gtggtatggc tgtgcaggct gtaaatcact gcataattcg 7200  
tgtcgctcaa ggccgactcc cgttctggat aatgtttttt gcgcgcacat cataacgggt 7260  
ctggcaataa ttctgaaatg agctgttgac aattaatcat cggctcgtat aatgtgtgga 7320

attgtgagcg gataacaatt tcacacagga aacagacccat gaggggaagcg gtgatcgccg 7380  
 aagtatcgac tcaactatca gaggtagtgt gcgtcatoga gcgccatctc gaaccgacgt 7440  
 tgctggccgt acatttgtac ggctccgcag tggatggcgg cctgaagcca cacagtgata 7500  
 ttgatttgcgt ggttacgggtg accgtaaggc ttgatgaaac aacggcgcca gctttgatca 7560  
 acgacctttt ggaaacttgc gcttcccctg gagagagcga gattctccgc gctgtagaag 7620  
 tcaccattgt tgtgcaogac gacatcattc cgtggcggtta tccagctaag cgcgaactgc 7680  
 aatttggaga atggcagcgc aatgacattc ttgcagggtat ctccagacca gccacgatcg 7740  
 acattgatct ggctatcttg ctgacaaaag caagagaaca tagcggttgc ttggtaggtc 7800  
 cagcggcgga ggaactcttt gatccgggtc ctgaacagga tctatttgag gcgctaaatg 7860  
 aaaccttaac gctatggaac tcgcgcgccg actgggctgg cgatgagcga aatgtagtgc 7920  
 ttacgttgct ccgcatttgg tacagcgag taaccggcaa aatcgcgccg aaggatgtcg 7980  
 ctgcgcactg ggcaatggag cgcctgccgg cccagtatca gcccgtcata cttgaagcta 8040  
 ggcaaggctta tcttggacaa gaagatcgct tggcctcgcg cgcagatcag ttggaagaat 8100  
 ttgttacta cgtgaaaggc gagatcacca aggtagtctg caaataaagc tctagtggat 8160  
 ccccgaggaa tcggcgtagc ggtcgcaaac catccggccc ggtacaaatc ggccggcgcg 8220  
 tgggtgatga cctgggtggag aagttgaagg ccgcgcaggc cgccagcgcg caacgatcg 8280  
 aggcagaagc acgccccggt gaatcggtggc aagcggccgc tgatcgaatc cgcaaagaat 8340  
 cccggcaacc gccggcagcc ggtgcgcgt cgattaggaa gccgccaag ggccgacgagc 8400  
 aaccagattt tttcgttccg atgctctatg acgtgggcac ccgcgatagt cgcagcatca 8460  
 tggacgtggc cgttttccgt ctgtcgaaag cgtgaccgag agctggcgag gtgatccgct 8520  
 acgagcttcc agacgggcac gtagagggtt cagcagggcc ggccggcatg gccagtgtgt 8580  
 gggattacga cctgggtactg atggcggtt cccatctaac cgaatccatg aaccgatacc 8640  
 gggaaggga gggagacaag cccggccgcg tgttcgtcc acacgttgcg gacgtactca 8700  
 agttctgcg gcgagccgat ggccgaaagc agaaagacga cctggtagaa acctgcattc 8760  
 ggttaaacac cagcacggt gccatgcagc gtacgaagaa ggccaagaac ggccgcctgg 8820  
 tgacggatc cgagggtgaa gccttgatta gccgtacaa gatcgtaaag agcgaaaccg 8880  
 ggccggccga gtacatcgag atcgagctag ctgattggat gtaccgcgag atcacagaag 8940  
 gcaagaaccc ggacgtgctg acggttcacc ccgattactt tttgatcgat cccggcatcg 9000  
 gcggttttct ctaccgcctg gcacgcgcg ccgcaggcaa ggcagaagcc agatggttgt 9060  
 tcaagacgat ctacgaacgc agtggcagcg ccggagagtt caagaagttc tgtttcaccg 9120  
 tgcgaagct gatcggttca aatgacctgc cggagtacga tttgaaggag gaggcgggcg 9180  
 aggttgccc gatcctagtc atgcgtacc gcaacctgat cgaggcgga gcatccgcg 9240  
 gttcctaagt tacggagcag atgctaggcg aaattgccct agcaggggaa aaaggtcgaa 9300  
 aaggtctctt tctgtggat agcacgtaca ttgggaaccc aaagccgtac attgggaacc 9360  
 ggaacccgta cattgggaac ccaaagccgt acattgggaa ccggtcacac atgtaagtga 9420  
 ctgatataaa agagaaaaaa ggcgattttt ccgcctaaaa ctcttataaa cttattataa 9480  
 ctcttaaaac ccgcctggcc tgtgcataac tgtctggcca gcgcacagcc gaagagctgc 9540  
 aaaaagcgcc tacccttcgg tcgctgcgct cctacgccc ccgcgcttcg cgtcggccta 9600  
 tcgcggccgc tggccgctca aaaatggctg gcctacggcc aggcacatca ccaggcgcg 9660  
 gacaagccgc gccgtcgcca ctgcaccgcc ggccgtgagg tctgcctcgt gaagaagggtg 9720  
 ttgctgactc ataccaggcc tgaatcgccc catcatccag ccagaaagtg agggagccac 9780  
 ggttgatgag agctttgttg taggtggacc agttggtgat tttgaacttt tgccttgcca 9840  
 cggaacggtc tgcgttgtcg ggaagatgcg tgatctgac cttcaactca gcaaaagttc 9900  
 ccaattatcc aattctgatt agaaaaactc atcgagcatc aaatgaaact gcaatttatt 10020  
 catatcagga ttatcaatac catatttttg aaaaagccgt ttctgtaatg aaggagaaaa 10080  
 ctcaccgagg cagttccata ggatggcaag atcctggtat cgtctgcga ttccgactcg 10140  
 tccaacatca atacaaccta ttaatttccc ctgctcaaaa ataaggttat caagtggaga 10200  
 atcaccatga gtgacgactg aatccgggtg gaatggcaaa agctctgcat taatgaatcg 10260  
 gccaacgcgc ggggagaggc ggtttgcgta ttggcgctc ttccgcttc tcgctcactg 10320  
 actcgctgcg ctcggtgctt cggctgcggc gagcggtatc agctcactca aaggcggtga 10380  
 tacggttatc cacagaatca ggggataacg caggaaagaa catgtgagca aaaggccagc 10440  
 aaaaggccag gaaccgtaaa aaggccgcgt tgcgtggcgt tttccatagg ctccgcccc 10500  
 ctgacgagca tcacaaaaat cgacgctcaa gtcagagggt gcgaaaccgc acaggactat 10560  
 aaagatacca ggcgtttccc cctggaagct ccctcgtcg ctctcctgt cgcaccctgc 10620  
 cgcttaccgg atacctgtcc gcctttctcc ctccgggaag cgtggcgctt tctcaatgct 10680

```

cacgctgtag gtatctcagt tcggtgtagg tcgttcgctc caagctgggc tgtgtgcacg 10740
aaccccccg ttagcccgac cgctgcgcct tatccggtaa ctatcgtctt ggtccaacc 10800
cggtaagaca cgacttatcg ccactggcag cagccactgg taacaggatt agcagagcga 10860
ggtatgtagg cgggtgctaca gagttcttga agtgggtggc taactacggc tacactagaa 10920
ggacagtatt tggatctctgc gctctgctga agccagttac cttcggaaaa agagttggta 10980
gctcttgatc cggcaaacaa accaccgctg gtagcgggtg tttttttgtt tgcaagcagc 11040
agattacgcg cagaaaaaaa ggatctcaag aagatccttt gatcttttct acgggggtctg 11100
acgctcagtg gaacgaaaac tcacgttaag ggattttgtt catgagatta tcaaaaagga 11160
tcttcaccta gatccttttg atccggaatt aattcctgtg gttggcatgc acatacaaat 11220
ggacgaacgg ataaaccttt tcacgccctt ttaaatatcc gattattcta ataaacgctc 11280
ttttcttta ggtttaccgg ccaatatatc ctgtcaaaca ctgatagttt aaactgaagg 11340
cgggaaacga caatctgatc atgagcggag aattaaggga gtcacgttat gacccccgcc 11400
gatgacgagg gacaagccgt tttagctttg gaactgacag aaccgcaacg ctgcaggaat 11460
t

```

Int'l Application No  
PC/EP 00/04117

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 C12N15/11 C12N15/63 C12N15/82 A01N63/00 A01H5/00

**B. FIELDS SEARCHED**

IPC 7 C12N A01N A01H

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

EPO-Internal, BIOSIS, WPI Data

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WATERHOUSE ET AL: "Virus resistance and gene silencing in plants can be induced by simultaneous expression of sense and antisense RNA"</p> <p>PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA,US,NATIONAL ACADEMY OF SCIENCE. WASHINGTON, vol. 95, no. 95, November 1998 (1998-11), pages 13959-13964, XP002114472</p> <p>ISSN: 0027-8424</p>	<p>1-7,23, 27,28, 30-33</p>
Y	<p>the whole document</p> <p style="text-align: center;">—</p> <p style="text-align: center;">-/-</p>	<p>10-13</p>

☒ Patent family members are listed in annex.

"A" document member of the same patent family

**21/09/2000**

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3018

**Maddox, A**



# INTERNATIONAL SEARCH REPORT

Intr "onal Application No

PCT/EP 00/04117

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	SIJEN TITIA ET AL: "RNA-mediated virus resistance: Role of repeated transgenes and delineation of targeted regions." PLANT CELL, vol. 8, no. 12, 1996, pages 2277-2294, XP002146482 ISSN: 1040-4651	1-6, 10-13, 27,30-33
Y	page 2284, left-hand column	10-13
P,X	WO 99 53050 A (WANG MING BO ;COMMW SCIENT IND RES ORG (AU); GRAHAM MICHAEL WAYNE) 21 October 1999 (1999-10-21) the whole document	1-7,23, 24,27, 28,30-33
P,X	WO 99 49029 A (GENE AUSTRALIA LIMITED AG ;GRAHAM MICHAEL WAYNE (AU); RICE ROBERT) 30 September 1999 (1999-09-30)  the whole document	1-6,8, 10-13, 18,27, 28,30-33
P,X	WO 99 32619 A (CARNEGIE INST OF WASHINGTON ;MONTGOMERY MARY K (US); FIRE ANDREW ( ) 1 July 1999 (1999-07-01) claims 1,5	1,27
A	BAULCOMBE D: "Mechanisms of pathogen-dereived resistance to viruses in transgenic plants" PLANT CELL,US,AMERICAN SOCIETY OF PLANT PHYSIOLOGISTS, ROCKVILLE, MD, vol. 8, no. 10, 1 October 1996 (1996-10-01), pages 1833-1844, XP002095878 ISSN: 1040-4651 the whole document	1-33
A	WO 98 36083 A (ANGELL SUSAN MARY ;BAULCOMBE DAVID CHARLES (GB); PLANT BIOSCIENCE) 20 August 1998 (1998-08-20) the whole document	1-33
A	WO 99 15682 A (LEDERER CARSTEN WERNER ;BAULCOMBE DAVID CHARLES (GB); VOINNET OLIV) 1 April 1999 (1999-04-01) the whole document	1-33
A	WO 98 37223 A (CORNELL RES FOUNDATION INC) 27 August 1998 (1998-08-27) the whole document	1-33
A	WO 98 53083 A (LOWE ALEXANDRA LOUISE ;GRIERSON DONALD (GB); ZENECA LTD (GB); HAMI) 26 November 1998 (1998-11-26) the whole document	10-13
	— -/-	

# INTERNATIONAL SEARCH REPORT

Int'l Application No  
PCT/EP 00/04117

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	MONTGOMERY M K ET AL: "Double-stranded RNA as a mediator in sequence-specific genetic silencing and co-suppression" TRENDS IN GENETICS,NL,ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, vol. 14, no. 7, 1 July 1998 (1998-07-01), pages 255-258, XP004124680 ISSN: 0168-9525 the whole document	1-33
A	GRANT SARAH R: "Dissecting the mechanisms of posttranscriptional gene silencing: Divide and conquer." CELL, vol. 96, no. 3, 5 February 1999 (1999-02-05), pages 303-306, XP002146483 ISSN: 0092-8674 the whole document	1-33
A	WO 90 14090 A (HEM RES INC) 29 November 1990 (1990-11-29) page 5	25,26
P,A	WO 99 61631 A (NOVARTIS ERFINDUNGEN VERWALTUN ;NOVARTIS AG (CH); HEIFETZ PETER BE) 2 December 1999 (1999-12-02) the whole document	1-33
E	WO 00 44914 A (FARRELL MICHAEL J ;LI YIN XIONG (US); KIRBY MARGARET L (US); MEDIC) 3 August 2000 (2000-08-03) claims 1,6,7	1,27

# INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/EP 00/04117

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9953050 A	21-10-1999	AU 2951499 A	01-11-1999
WO 9949029 A	30-09-1999	NONE	
WO 9932619 A	01-07-1999	AU 1938099 A	12-07-1999
WO 9836083 A	20-08-1998	AU 6001698 A EP 0970228 A	08-09-1998 12-01-2000
WO 9915682 A	01-04-1999	AU 9175198 A EP 1017831 A AU 6001698 A EP 0970228 A	12-04-1999 12-07-2000 08-09-1998 12-01-2000
WO 9837223 A	27-08-1998	AU 6657198 A CN 1252102 T EP 0970237 A	09-09-1998 03-05-2000 12-01-2000
WO 9853083 A	26-11-1998	AU 7444298 A EP 0983370 A	11-12-1998 08-03-2000
WO 9014090 A	29-11-1990	EP 0473576 A JP 4507083 T	11-03-1992 10-12-1992
WO 9961631 A	02-12-1999	AU 4368399 A	13-12-1999
WO 0044914 A	03-08-2000	NONE	

**THIS PAGE BLANK (USPTO)**